Compositions and methods for reduction of amyloid-beta load

ABSTRACT

The present invention relates to methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of Aβ levels via selective modulation (e.g., inhibition) of γ-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an Aβ-related disorder, by administering a compound that results in the modulation of γ-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain Aβ disorder, such as Alzheimer&#39;s disease.

This application is a continuation of U.S. patent application Ser. No.14/354,059, filed Apr. 24, 2014, which is a § 371 national entryapplication of PCT/US2012/063025, filed Nov. 1, 2012, which claimspriority to U.S. Provisional Application Ser. Nos. 61/554,375, filedNov. 1, 2011 and 61/682,031, filed Aug. 10, 2012, each of which isincorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to methods and compositions for modulatinglevels of amyloid-β peptide (Aβ) exhibited by non-neural (i.e.,peripheral) cells, fluids, or tissues. The invention also relates tomodulation of brain Aβ levels via selective modulation (e.g.,inhibition) of γ-secretase activity in peripheral tissues. The inventionfurther relates to methods of preventing, treating or ameliorating thesymptoms of a disorder, including but not limited to a neural Aβ-relateddisorder, by peripherally administering a compound that results in themodulation of γ-secretase, either directly or indirectly. The inventionalso relates to the use of modulators of γ-secretase activity viaperipheral administration to prevent, treat or ameliorate the symptomsof Alzheimer's disease. The invention still further relates to the useof inhibitors of Aβ production that have reduced kinase inhibitionactivity.

BACKGROUND

Amyloid-β (Aβ) peptides are metabolites of the Alzheimer'sdisease-associated precursor protein, β-amyloid precursor protein (APP),and are believed to be the major pathological determinants ofAlzheimer's disease (AD). AD is a neurodegenerative disordercharacterized by the age-dependent deposition of Aβ within vulnerableregions of the brain, particularly the frontal cortex and hippocampus(Terry R D. J Geriatr Psychiatry Neurol 19:125-128, 2006). Aβ has apathogenic effect, leading to progressive neuronal loss that causesdeterioration of the ability of those brain regions to orchestrate bothhigher order and basic neural processes. As the deterioration worsens,the affected individual faces dementia and a worsening quality of life,and eventually the condition is fatal (Brookmeyer R, Johnson E,Ziegler-Graham K, Arrighi H M. Alzheimer's Dement 3:186-191, 2007;Powers J M. Neurobiol Aging 18:S53-S54, 1997).

It is believed that the development of AD is the consequence of thenatural biochemical processes associated with aging, and that nearlyevery individual would eventually manifest symptoms of the disease werehe or she to live long enough. Age is the greatest known risk factor forAD with an incidence of 25-50% in people aged 85 years or older(Giacobini E. Ann NY Acad Sci 920:321-327, 2000). For a givenindividual, the time at which the disorder manifests is the consequenceof an additional series of risk factors, some of which might be due toenvironmental causes, but many of which are due to that individual'sgenetic endowment: natural variations in the structures and activitiesof an individual's genes produces ensembles of proteins whose complexwebs of interactions render that individual more or less prone to AD.Some of the genes whose protein products affect AD risk have beenidentified. For example, there are three common variants of the genethat encodes the serum protein Apolipoprotein E, called e2, e3 and e4.Individuals who inherit an e4-encoding allele are at higher risk thanaverage for AD and tend to develop disease at earlier times thanindividuals with no e4 alleles. Those who inherit e4 alleles from bothparents are at even higher risk for early-onset AD, while individualswith e2 alleles are at very low risk, developing the disease later inlife than the average if at all (Cedazo-Minguez A. J Cell Mol Med.11:1227-38, 2007). Traumatic brain injury and repetitive brain traumahave also been found to accelerate brain Aβ deposition and cognitiveimpairment. Uryu et al. J. Neurosci. 22 (2): 446 (2002).

Most if not all AD is considered to have some genetic component that islinked to the risk threshold for each individual. However, some forms ofhuman AD are particularly highly heritable. These heritable forms arecaused by rare mutations in single genes that encode proteins that areassociated with this neurodegenerative disorder and that play centralroles in the initiation of the disease process. Mutations in these genescan be inherited or can arise sporadically.

One of these genes encodes the Amyloid Precursor Protein (APP) (Tanzi RE. Ann Med. 21:91-94, 1989). APP is a membrane protein whose biochemicalfunction is at present unknown. It is known that APP is a substrate forproteolysis by several endogenous proteases, and that proteolysisliberates fragments having various structures. Two of the proteaseactivities are referred to as β-secretase and γ-secretase. Proteolysisof APP by β-secretase generates a fragment that can subsequently becleaved by γ-secretase at multiple sites to produce Aβ peptides.γ-secretase is complex of several proteins (including presenilin 1 andpresenilin 2), and cleavage of APP by γ-secretase produces multipleisoforms of Aβ, which range from 37 to 43 amino acid residues (see,e.g., Steiner H, Fluhrer R, Haass C., J Biol Chem. 2008 Jul. 23). A42-residue form of Aβ is thought to be the most pathogenic (Wolfe M S.Biochemistry 45:7931-7939, 2006). The 42-residue Aβ fragment formsoligomeric structures, which, in addition to forming the plaques thatdeposit in the AD-affected brain, are thought to cause cognitivedeficits (Barten D M, Albright C F. Mol Neurobiol 37:171-186, 2008).

Variations in APP that predispose to AD cluster in the vicinity of theproteolytic cleavage sites, affecting the rate at which pathogenic Aβfragments are generated, their stability, and their ability to formoligomers (Selkoe D J. Physiol Rev 81:741-766, 2001). Individualsinheriting such APP variations usually show signs of AD in their 50s,whereas sporadic AD is not common until individuals reach their 70s(Waring S C, Rosenberg R N. Arch Neurol. 65:329-34, 2008).

The complete molecular identity of γ-secretase enzyme is still unknown.Presenilin 1, or the closely related presenilin 2, is needed forγ-secretase activity. γ-secretase activity is reduced 80% in culturedcells derived from embryos genetically deleted for presenilin 1. Allγ-secretase activity is lost in cells lacking both presenilin 1 andpresenilin 2. Peptidomimetic inhibitors of γ-secretase activity can becrosslinked to presenilins 1 and 2, suggesting that these proteins arecatalytic subunits for the cleavage. However, γ-secretase activityisolated from cells chromatographs as a large complex >1M daltons.Recent genetic studies have identified three more proteins required forγ-secretase activity; nicastrin, aph-1 and pen-1. (Francis et al., 2002,Developmental Cell 3(1): 85-97; Steiner et al., 2002, J. Biol.Chemistry: 277(42): 3906239065; and Li et al., 2002, J. Neurochem.82(6): 1540-1548). Accumulation of presenilin into high molecular weightcomplexes is altered in cells lacking these proteins. Rare variations inthe genes encoding the presenilin 1 and presenilin 2 components ofγ-secretase also confer high risk to early-onset AD (Waring S C,Rosenberg R N. Arch Neurol. 65:329-34, 2008).

A third enzyme, α-secretase, cleaves the precursor protein between theβ- and γ-cleavage sites, precluding Aβ production and releasing anapproximately 3 kDa peptide known as P3, which is non-pathological. Bothβ- and α-secretase cleavage also result in soluble, secreted terminalfragments of APP, known as sAPPβ and sAPPα, respectively. The sAPPαfragment has been suggested to be neuroprotective.

As a consequence of these genetic observations and considerablebiochemical and neuroanatomical experimentation, the model has emergedthat biochemical events that increase the production and accumulation ofAβ, particularly Aβ-42, accelerate the onset and progression of AD.Therapeutic and prophylactic programs, therefore, have been targeted atreducing the production of Aβ or lower its accumulation.

The current focus of AD treatment is lowering of Aβ production and/oraccumulation in the brain. Several approaches are presently underinvestigation (Rojas-Fernandez C H, Chen M, Fernandez H L.Pharmacotherapy 22:1547-1563, 2002; Hardy J, Selkoe D J. Science.297:353-356, 2002). Mice that are transgenic for AD-predisposing APP andthat additionally carry an inactivating knockout mutation in theβ-secretase gene exhibit nearly complete reductions of Aβ in the brain(Luo Y, Bolon B, Kahn S, Bennett B D, Babu-Khan S, Denis P, Fan W, KhaH, Zhang J, Gong Y, Martin L, Louis J C, Yan Q, Richards W G, Citron M,Vassar R. Nat Neurosci 4:231-232, 2001). However, it has beendemonstrated that such mice nonetheless exhibit cognitive deficits,premature death, and hypomyelination (Ohno M, Chang L, Tseng W, OakleyH, Citron M, Klein W L, Vassar R, Disterhoft J F. Eur J Neurosci23:251-260, 2006; Ohno M, Sametsky E A, Younkin L H, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft J F. Neuron 41:27-33, 2004; Laird F M,Cai H, Savonenko A V, Farah M R, He K, Melnikova T, Wen H, Chiang H-C,Xu G, Koliatsos V E, Borchelt D R, Price D L, Lee H-K, Wong P C. JNeurosci 25:11693-11709, 2005; Dominguez D, Tournoy J, Hartmann D, HuthT, Cryns K, Deforce S, Serneels L, Camacho I E, Marjaux E, CraessaertsK, Roebroek A J, Schwake M, D'Hooge R, Bach P, Kalinke U, Moechars D,Alzheimer C, Reiss K, Saftig P, De Strooper B. J Biol Chem280:30797-30806, 2005; Hu X, Hicks C W, He W, Wong P, Macklin W B, TrappB D, Yan R. Nat Neurosci 9:1520-1525, 2006). This leads to theconclusion that β-secretase activity in the brain is necessary forhealthy neural function, and therapeutics that lower brain activity ofβ-secretase might have adverse side effects. In addition, it has beendifficult to design potent, brain penetrant β-secretase inhibitors(Barten D M, Albright C F. Mol Neurobiol 37:171-186, 2008), which hasbeen the goal of those who work on the pharmacotherapy of AD.

The effects of γ-secretase inhibitors in reducing brain Aβ have alsobeen investigated. Brain-penetrant γ-secretase inhibitors have beenshown to reduce Aβ synthesis and reduce cognitive deficits in mousemodels of AD (Barten D M, Meredith J E Jr, Zaczek R, Houston J G,Albright C F. Drugs R D 7:87-97, 2006). However, γ-secretase has targetsin addition to APP (Pollack S J, Lewis H. Curr Opin Investig Drugs6:35-47, 2005), one of which is the Notch family of transmembranereceptors. Inhibition of Notch signaling by chronic dosing ofγ-secretase inhibitors causes changes in the gastrointestinal tract,spleen, and thymus that limit the extent of Aβ inhibition attainable invivo using the studied compounds (Searfoss G H, Jordan W H, Calligaro DO, Galbreath E J, Schirtzinger L M, Berridge B R, Gao H, Higgins M A,May P C, Ryan T P. J Biol Chem 278:46107-46116, 2003; Wong G T, ManfraD, Poulet F M, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M,Fine J S, Lee H J, Zhang L, Higgins G A, Parker E M. J Biol Chem279:12876-12882, 2004; Milano J, McKay J, Dagenais C, Foster-Brown L,Pognan F, Gadient R, Jacobs R T, Zacco A, Greenberg B, Ciaccio P J.Toxicol Sci 82:341-358, 2004).

U.S. Patent Application 20020128319 A1 states that certain nonsteroidalanti-inflammatory drugs (NSAIDS) lower production and/or levels of Aβ42in cell cultures expressing Aβ40 and Aβ42 derived from the cleavage ofAPP. Since there is good evidence that high Aβ42 levels are a major riskfactor for AD, such drugs may be useful in preventing, delaying orreversing the progression of AD. The drawback of the use of such drugs,however, is that large doses of NSAIDS are required for significantlowering of Aβ42, and significant gastrointestinal side effects,including bleeding ulcers, are associated with prolonged use of NSAIDSat high doses (Langman et al., 1994, Lancet 343:1075-1078). In addition,there remains an unknown risk for Alzheimer's disease due to amyloidformation from Aβ40 and other forms unaffected by Aβ42 lowering agents.There is, therefore, a need in the art to develop treatments fordiseases or disorders related to the regulation of Aβ production.

One class of compounds has been found to reduce Aβ production withoutaffecting Notch signaling. This class of compounds includes the tyrosinekinase inhibitor imatinib mesylate (STI-571, trade name GLEEVEC) and therelated compound,6-(2,6-dichlorophenyl)-8-methyl-2-(methylsulfanylphenyl-amino)-8H-pyrido[2,3-d]pyrimidin-7-one,referred to as inhibitor 2 (Netzer W J, et al., Proc Natl Acad Sci USA.100:12444-12449, 2003). See also US Patent Publication 2004/0028673 andPCT patent publication WO 2004/032925, each incorporated herein byreference. STI-571 is presently approved for treatment of myelogenousleukemia and gastrointestinal stromal tumors. STI-571 potently reducesthe production of Aβ, both in APP-transfected neuroblastoma cells and incell-free extracts of transfected cells, via a mechanism that does notrequire the Abl tyrosine kinase, one of the important targets of thisdrug in leukemia cells (Netzer, supra). STI-571 and a related compoundcalled “Inhibitor 2” were found to reduce production of Aβ in culturesof primary neurons prepared from cerebral cortex of embryonic day 18rats (Netzer, supra), indicating that these drugs affect proteolyticprocessing of proteins from both endogenous and transfected APP genes.

STI-571, according to the product literature for GLEEVEC, isadministered orally. The drug has been investigated for its effect on Aβaccumulation in brain and the drug has been shown to have poorpenetration of the blood-brain barrier. In a STI-571-treated leukemiapatient who received the drug, the cerebral spinal fluid (CSF) level ofthe drug was 92-fold lower than the level in the blood (Takayama N, SatoN, O'Brien S G, Ikeda Y, Okamoto S. Br J Haematol. 119:106-108, 2002).Therefore, its utility in unmodified form as a potential therapeutic forAD has been dismissed (Netzer, supra).

In view of the poor penetration of the blood-brain barrier, researchersinvestigating the effect of STI-571 on brain Aβ have used implantedosmotic minipumps to deliver STI-571 or inhibitor 2 intrathecally to thebrains of guinea pigs (Netzer, supra). While Netzer, et al. observed adecrease in Aβ accumulation in brain, they nonetheless concluded “In thecase of Gleevec and related drugs, the ability to achieve a high degreeof penetration of the blood-brain barrier would be necessary to improvethe likelihood of therapeutic benefit.” (Netzer, supra).

In the development of small molecule therapeutics for most diseases,compounds that inhibit protein kinases or block the ATP-binding domainof any enzyme are generally less preferable than compounds exerting thesame therapeutic action via alternative mechanisms. Protein kinasesregulate a number of essential cellular processes, including cell cycleprogression, DNA damage response, cell proliferation, metabolism andcell death, differentiation and survival. Indeed, the human genomecontains at least 500 distinct genes encoding protein kinases. Thekinase inhibitor drugs, such as imatinib have known off-targetinteractions that alter their toxicity and side-effect profiles (see,e.g., Force, T. & Kolaja, K. L. Cardiotoxicity of kinase inhibitors: theprediction and translation of preclinical models to clinical outcomes.Nat. Rev. Drug Discov. 10, 111-126 (2011)). Imatinib inhibits thekinases Abl, ARG (Abl-related gene protein), PDGF-Ra/B and KIT. Thetyrosine kinase inhibitor sunitinib (see e.g., Chu, T. F. et al.Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.Lancet 370, 2011-2019 (2007)) and other kinase inhibitors exhibitcardiotoxicity (see also Cheng, H. & Force, T. Molecular mechanisms ofcardiovascular toxicity of targeted cancer therapeutics, Circ. Res. 106,21-34 (2010)). Thus, there is concern that of use of kinase-inhibitingdrugs such as imatinib in long-term therapeutic regimens to preventAlzheimer's disease might have negative consequences that are notobserved in relatively brief chemotherapeutic regimens. Even though thereported side effects of imatinib are considered modest for achemotherapeutic agent used in cancer treatments, it may be expectedthat new side effects linked to the protein kinase inhibition activitywould be observed if tens of millions of people were to take the drug ona maintenance basis.

There remains a need for treatments to effectively reduce the levels ofAβ in brain, and there further remains a need for treatments thateffectively reduce levels of Aβ, and that result in less inhibition ofAbl kinase activity.

SUMMARY OF THE INVENTION

The present invention relates to methods of treating, preventing ormonitoring a brain Aβ disorder, by testing and/or treating peripheral(non-brain, non-CNS) tissues. In some preferred embodiments, theperipheral tissue comprises liver, while in other embodiments, theperipheral tissue comprises blood/and or serum. In some embodiments, thepresent invention comprises assessing a subject for the presence of ADor predisposition to AD, peripherally administering a compound thatmodulates accumulation or production of Aβ, and assessing said subjectfor AD or progression of AD.

The present invention provides methods, compositions and processesrelated to treatment or prevention of AD by treating the liver of asubject. In particular, the present invention relates to altering Aβproduction, processing, accumulation or transport in the liver of asubject by direct inhibition of production (e.g., by inhibition ofexpression of APP), or by modulating a factor that in turn modulatesproduction, processing, accumulation or transport of Aβ in liver. Suchfactors include but are not limited to γ-secretase, presenilin 1,presenilin 2, ApoE, calmyrin, neugrin, inositol 1,4,5-trisphosphatereceptor (InsP3R) or Smad-interacting protein-1 (SIP1, encoded byZfhxlb), clusterin (encoded by CLU, also known as ApoJ),phosphoinositol-binding clatherin assembly protein (encoded by PICALM),complement component receptor 1 (encoded by CR1), insulin degradingenzyme (IDE), gamma secretase-activating protein (GSAP), and modulatorsthereof. The invention encompasses the treatment or prevention of AD bymodulation of any factor that, when modulated, influences—eitherdirectly (e.g., by acting on APP production or processing) or indirectly(e.g., by acting on a factor that, in turn, acts on a factor that actson APP), the production of Aβ in liver of a subject. The invention isnot limited by the nature of the modulation, or the identity or numberof factors acted upon to modulate Aβ in the liver of a subject.

In some embodiments, the present invention provides methods of treatinga subject diagnosed with as having a brain Aβ disorder or predispositionto a brain Aβ disorder, comprising peripherally administering a compoundthat modulates production of Aβ in a peripheral tissue. In somepreferred embodiments, the compound inhibits production of Aβ. Inparticularly preferred embodiments, a peripherally administered compoundhas a partition coefficient of less than 2.0, more preferably less than1.5, and still more preferably less than about 1.0. In particularlypreferred embodiments, the compound does not substantially cross theblood-brain barrier.

In some embodiments, the present invention provides methods of treatinga subject for a brain Aβ disorder or predisposition to a brain Aβdisorder in a subject, comprising peripherally administering a compoundthat modulates expression of a gene in a peripheral tissue of saidsubject. In preferred embodiments, modulation of said expression of saidgene results in modulation of Aβ production or accumulation in saidperipheral tissue. In certain preferred embodiments, the peripheraltissue is the liver of a subject.

The present invention encompasses any method of influencing theproduction of Aβ in liver, including but not limited to alteringexpression and/or processing of APP. In some embodiments, the presentinvention provides methods comprising peripherally administering acompound that modulates expression of one or more of Psen 1, Apo E,InsP3R, Psen2, APP, Cib1, Ngrn, Zfhxlb, CLU (also known as ApoJ),PICALM, IDE, GSAP and CR1 genes. In some embodiments, the methods of thepresent invention comprises peripherally administering a compound thatmodulates the activity of one or more of presenilin 2, calmyrin,neugrin, Zfhxlb, clusterin, phosphoinositol-binding clatherin assemblyprotein, complement component receptor 1, insulin degrading enzyme,GSAP, or APP expression or activity. In some embodiments, one or more ofthese genes or activities is modulated in the liver of a subject. Insome embodiments, modulation comprises inhibition of expression oractivity, while in some embodiments, modulation comprises stimulation ofexpression or activity.

In some embodiments, the present invention comprises a method, e.g., oftreating a brain Aβ disorder, comprising the steps of assessing asubject for the presence of a brain Aβ disorder or predisposition to abrain Aβ disorder, peripherally administering a compound that modulatesproduction of Aβ, wherein the compound does not substantially penetratethe blood brain barrier, and assessing the subject for a brain Aβdisorder or progression of a brain Aβ disorder. It is furthercontemplated that, in some embodiments, the results of the assessmentpre and post treatment are compared, to determine, e.g., the effect oftreatment on the status of the brain Aβ disorder (e.g., to determine aneffect on onset or rate of development or relief of diseases).Modulation of production of Aβ is not limited to any particular means orpathway of modulation. Modulation of production may include, e.g.,alteration (e.g., reduction) of expression of APP, or alteration ofprocessing of APP into Aβ.

In some embodiments, the invention comprises the steps of assessing asubject for the presence of a brain Aβ disorder or predisposition to abrain Aβ disorder, peripherally administering a compound that modulatesaccumulation of Aβ, wherein the compound does not substantiallypenetrate the blood brain barrier, and assessing the subject for a brainAβ disorder or progression of a brain Aβ disorder. Modulation ofaccumulation of Aβ is not limited to any particular means. Modulation ofaccumulation may include, e.g., decreasing production of Aβ and/orincreasing degradation or clearance of Aβ, or alteration of Aβ toproduce a modified form with different properties (e.g., anon-pathogenic form).

It is contemplated that in some embodiments of the invention, themodulation of production and/or accumulation of Aβ, the compoundadministered comprises a modulator of a γ-secretase activity, while insome preferred embodiments, the compound comprises an inhibitor of aγ-secretase activity.

It is further contemplated that in some embodiments of the invention,the modulation of production and/or accumulation of Aβ, the compoundadministered comprises a modulator of Presenilin 2. In some preferredembodiments, the compound comprises an inhibitor of Presenilin 2. Insome embodiments, the compound comprises a modulator of cleavage ofamyloid precursor protein, while in some embodiments, the compoundcomprises an inhibitor of cleavage of amyloid precursor protein.

In some embodiments, the compound comprises a composition selected fromthe group consisting of STI-571, imatinib para-diaminomethylbenzene(e.g., trihydrochloride), N-desmethyl imatinib, Compound 1, Compound 2,LY450139, GSI-953, Flurizan, and E2012 (Eisei) compound, or ablood-brain barrier impermeable variant thereof. In particularlypreferred embodiments, the composition has a partition coefficient(e.g., in an octanol/water system) of less than 2.0, more preferablyless than 1.5, and still more preferably less than about 1.0. Inparticularly preferred embodiments, the compound does not substantiallycross the blood-brain barrier.

In some embodiments, the compound comprises an interferingoligonucleotide, while in preferred embodiments, the compound comprisesinterfering RNA. In still more preferred embodiments, the interferingRNA is selected from the group consisting of siRNA, shRNA and miRNA. Insome embodiments, the interfering RNA comprises an interfering RNAdirected toward amyloid precursor protein RNA, while in otherembodiments, the interfering RNA comprises an interfering RNA directedtoward Presenilin 2 RNA. In other embodiments the interfering RNA isdirected against the Psen 1, Apo E, InsP3R, Cib1, Ngrn, Zfhxlb, CLU(also known as ApoJ), PICALM, IDE, GSAP or CR1 RNA.

It is contemplated that in some embodiments, the compound furthercomprises a known therapeutic agent for treating, ameliorating, orreducing risk or severity of a brain Aβ-related disorder. In certainpreferred embodiments, the known therapeutic agent is selected from thegroup consisting of cannabinoids, dimebom, prednisone, ibuprofen,naproxyn, indomethacin; statins, selective estrogen receptor molecules,antihypertensives, alpha-blockers, beta-blockers, alpha-beta blockers,angiotensin-converting enzyme inhibitors, angiotensin receptor blockers,calcium channel blockers, diuretics, and antioxidants.

The peripheral administration of said compound in the method of thepresent invention is not limited to any particular route. Routes ofadministration include but are not limited to through the eyes(ophthalmic), mouth (oral), skin (transdermal), nose (nasal), lungs(inhalant), oral mucosa (buccal), ear, by injection (e.g.,intravenously, subcutaneously, intraperitoneally, etc.) and the like. Incertain preferred embodiments, the peripherally administering comprisesorally administering.

In some embodiments of the methods of the present invention, theassessing comprises a mental status evaluation. In some preferredembodiments, the assessing comprises one or more of neuropsychologicaltesting and brain imaging.

It is contemplated that in some embodiments, the present inventionprovides a method of assessing risk of or presence of a brain Aβdisorder in a subject, comprising determining a level of Aβ in aperipheral tissue of said subject. In some other embodiments, theinvention provides a method of monitoring a brain Aβ disorder in asubject, comprising determining a level of Aβ in a peripheral tissue ofsaid subject. In some embodiments, the peripheral tissue is blood, whilein some embodiments, the peripheral tissue is serum. In someparticularly preferred embodiments, monitoring comprises measuring Aβ insaid peripheral tissue at a plurality of time points.

In preferred embodiments of the methods disclosed hereinabove, the brainAβ disorder is Alzheimer's disease.

In some embodiments, the present invention provides methods ofmonitoring a brain Aβ disorder in a subject comprising analysis ofexpression or activity of a gene product in peripheral tissue of saidsubject. In certain preferred embodiments, the gene product is from agene selected from the group consisting of Psen2, APP, Cib1, Ngrn, andZfhxlb.

In some embodiments, the present invention provides a method, comprisingthe steps of assessing a subject for the presence of a brain Aβ disorderor predisposition to a brain Aβ disorder, and peripherally administeringa compound that inhibits the transport of peripheral Aβ across the bloodbrain barrier, wherein said compound is not an anti-Aβ antibody. Inpreferred embodiments, the further comprises assessing said subject fora brain Aβ disorder or progression of a brain Aβ disorder. Inparticularly preferred embodiments, the brain Aβ disorder is Alzheimer'sdisease.

In some embodiments, the present invention provides a method ofidentifying a genetic target for treatment of a brain Aβ disorder,comprising comparing a liver gene expression profile of offspring from afirst parent who has or who is predisposed to said Aβ disorder and asecond parent having reduced susceptibility to said Aβ disorder, toidentify a heritable genetic marker having a level of expression inliver, wherein increased or decreased expression of said heritablegenetic marker in liver of said offspring relative to the level ofexpression in the liver of said first parent correlates with inheritanceof said genetic marker from said second parent.

In some embodiments, the present invention comprises a compound selectedfrom the group consisting STI-571, imatinib para-diaminomethylbenzene,N-desmethyl imatinib, Compound 1, Compound 2, LY450139, GSI-953,Flurizan, and E2012 compound, or a blood-brain barrier impermeablevariant thereof, for use in the modulation of production of Aβ inperipheral tissue of a subject having or predisposed to developing a Aβdisorder. In some embodiments, the Aβ disorder is a brain Aβ disorder.In particularly preferred embodiments, the compound has a partitioncoefficient of less than 2.0, more preferably less than 1.5, and stillmore preferably less than about 1.0. In particularly preferredembodiments, the compound does not substantially cross the blood-brainbarrier.

In some embodiments, the present invention provides a compound selectedfrom the group consisting STI-571, imatinib para-diaminomethylbenzene,N-desmethyl imatinib, Compound 1, Compound 2, LY450139, GSI-953,Flurizan, and E2012 compound, or a blood-brain barrier impermeablevariant thereof, for use in the modulation (e.g., inhibition) ofproduction of Aβ in liver of a subject having or predisposed todeveloping an Aβ disorder. In some embodiments, the Aβ disorder is abrain Aβ disorder. In particularly preferred embodiments, the compoundhas a partition coefficient of less than 2.0, more preferably less than1.5, and still more preferably less than about 1.0. In particularlypreferred embodiments, the compound does not substantially cross theblood-brain barrier.

In some embodiments, the invention relates to use of a compound selectedfrom the group consisting, imatinib (STI-571), imatinibpara-diaminomethylbenzene, N-desmethyl imatinib, WGB-BC-15, Compound 1,Compound 2, LY450139, GSI-953, Flurizan, and E2012 compound, ablood-brain barrier impermeable variant thereof, and/or apharmaceutically acceptable salt thereof, for the manufacture of amedicament for the modulation of production of Aβ in a peripheral tissueof a subject having or predisposed to developing a brain Aβ disorder Inpreferred embodiments, the medicament is formulated for oraladministration. In particularly preferred embodiments, the peripheraltissue comprises liver. In still more particularly preferredembodiments, the compound has a partition coefficient of less than 2.0,preferably less than 1.5, and still more preferably less than about 1.0.In particularly preferred embodiments, the compound does notsubstantially cross the blood-brain barrier. In some preferredembodiments, the present invention relates to use of imatinib or apharmaceutically acceptable salt thereof in the manufacture of amedicament for the inhibition of production of Aβ in liver of a subjecthaving or predisposed to developing a brain Aβ disorder.

The invention also provides for the use of the compounds as describedabove for the manufacture of a medicament comprising a secondtherapeutic agent for the treatment of a brain Aβ disorder. In someembodiments, a second therapeutic agent is selected from imatinib(STI-571), imatinib para-diaminomethylbenzene, N-desmethyl imatinib,WGB-BC-15, Compound 1, Compound 2, LY450139, GSI-953, Flurizan, andE2012 compound, a blood-brain barrier impermeable variant thereof,and/or a pharmaceutically acceptable salt thereof. In certain preferredembodiments, the second therapeutic agent comprises one or more agentsselected from the group consisting of cannabinoids, dimebom, prednisone,ibuprofen, naproxyn, indomethacin; statins, selective estrogen receptormolecules, antihypertensives, alpha-blockers, beta-blockers, alpha-betablockers, angiotensin-converting enzyme inhibitors, angiotensin receptorblockers, calcium channel blockers, diuretics, and antioxidants. Incertain particularly preferred embodiments of the methods andcompositions described above, the compound comprises imatinibpara-diaminomethylbenzene and/or N-desmethyl imatinib, or apharmaceutically acceptable salt thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows a graph comparing the amount of Psen2 mRNA in liversamples from subject mice, compared to genotype of the mice at the Psen2locus.

FIG. 1B shows graphs plotting Psen2 locus genotype (B6/B6 or D2/D2) vs.Psen2 mRNA concentration in 6 tissues (arbitrary units) from the up to89 recombinant inbred (RI) lines. The parental C57 and DBA values areplotted next to those from the RI lines. Some tissues have data fromsingle RI lines that are heterozygous at the Psen2 locus: these arerepresented on the plots as B6/D2. Data obtained from GeneNetwork.org(J. Wang, R. W. Williams, K. F. Manly K F, Neuroinformatics 1, 299(2003)). For liver, expression data were initially expressed as theratio of the liver fluorescence signal to that generated by thereference mRNA sample for each probe. Data were normalized using arobust LOWESS smoothing method that adjusts for non-linearity of signalin the two channels. We then computed the log base 2 of these ratios(median). A value of −1 indicates that expression in liver is roughly ½that in the control; a value of −2 indicates that expression in theliver is roughly ¼ that in the control, etc. Conversely, a value of +2indicates that the expression in liver is 4-fold greater in liver. Liverdata set from 40 recombinant inbred lines described in by D. Gatti, etal., Hepatology 46, 548 (2007). For other tissues, expression values andalternative normalization methods were as indicated (Wang, supra).

FIG. 2 is a diagram of the chemical structures of STI-571, the mesylatesalt GLEEVEC™), STI-571 variant (“WGB-BC-15”), Compound 1 (PD173955,Moasser et al., 1999, Cancer Research 59: 6145-6152; Wisniewski et al.,Cancer Research 2002, 62(15):4244-55), and Compound 2 (PD166326;Wisniewski et al., Cancer Research 2002, 62(15):4244-55).

FIG. 3 shows the effects of peripherally administered STI-571 on thelevels of Aβ in plasma and whole brain. Wild-type B6 and D2 mice (age8-12 weeks [A-F] or 15-18 months[G,H]) were administered drug or vehicletwice daily for 7 days by intraperitoneal injection. Panel A showsWestern blots showing levels of Aβ hexamers in plasma from young D2 micetreated with saline vehicle (lanes 1, 2, 9 and 10) or STI-571 at threedoses: lanes 3, 4, 11, and 12 show results with 1 mg/kg; lanes 5, 6, 13and 14 show results with 10 mg/kg; and lanes 7, 8, 15 and 16 showresults with 100 mg/kg; n=4 per group. Panel B shows a bar graphquantification of the Western blot images in FIG. 3A. Panel C shows aWestern blot showing levels of Aβ hexamers in brain extracts from youngB6 mice treated with saline vehicle or STI-571 at 20 mg/kg (n=10 pergroup in total; only n=5 are shown in Western blot). Panel D shows a bargraph quantification of the Western blot images in Panel C. Panels E andF show bar graphs indicating levels of Aβ hexamers in brain extracts (E)or plasma (F) of old B6 mice treated with saline vehicle or STI-571 at20 mg/kg (n=4 per group).

FIG. 4 shows a graph comparing the amount of Ngrn mRNA in liver samplesfrom subject mice, compared to the genotype of the mice at the Ngrnlocus.

FIG. 5 shows graphs plotting of Cib1 (FIG. 5A) or Zfhxlb (FIG. 5B)genotype (B6/B6, B6/D2 or D2/D2) vs. calmyrin (FIG. 5A) or Zfhxlb (FIG.5B) mRNA concentration in liver (arbitrary units) for 40 recombinantinbred lines, as in FIG. 1B. Data obtained from GeneNetwork.org (Wang,supra); liver data set described by Gatti, supra.

FIG. 6 shows a graph comparing the effects of imatinib and desmethylimatinib on the concentration of Aβ in treated cells.

FIG. 7 shows shows a graph comparing the effects of imatinib, Imatinibpara-diaminomethylbenzene 3 HCl, imatinib (pyridine)-N-oxide, andimatinib (piperidine)-N-oxide on the concentration of Aβ in treatedcells.

FIG. 8 shows a graph comparing the effects of imatinib, desmethylimatinib, and imatinib para-diaminomethylbenzene on the Abl kinaseactivity in a cell-free assay system.

FIG. 9 shows a selectivity graph showing the ratio of the folddifference in Aβ-lowering activity for each compound (compared toimatinib) to the kinase inhibitor activity for that compound at each ofthe three concentrations shown.

FIG. 10 shows the structures of N-desmethyl imatinib, imatinibpara-diaminomethylbenzene 3 HCl, imatinib (pyridine)-N-oxide, andimatinib (piperidine)-N-oxide, respectively.

DEFINITIONS

As used herein, the terms “subject” and “patient” are usedinterchangeably. As used herein, the terms “subject” and “subjects”refer to an animal, preferably a mammal including a non-primate (e.g., acow, pig, horse, donkey, goat, camel, cat, dog, guinea pig, rat, mouse,sheep) and a primate (e.g., a monkey, such as a cynomolgous monkey,gorilla, chimpanzee, and a human), preferably a human. In oneembodiment, the subject is a subject with Alzheimer's disease (AD).

As used herein, the term “Aβ-related disorder” or an “Aβ disorder” is adisease (e.g., Alzheimer's disease) or a condition (e.g., seniledementia) that involves an aberration or dysregulation of Aβ levels. AnAβ-related disorder includes, but is not limited to AD, braintrauma-related amyloid disorders, Down's syndrome and inclusion bodymyositis.

As used herein, the term “at risk for disease” refers to a subject(e.g., a human) that is predisposed to experiencing a particulardisease. This predisposition may be genetic (e.g., a particular genetictendency to experience the disease, such as heritable disorders), or dueto other factors (e.g., age, weight, environmental conditions, exposuresto detrimental compounds present in the environment, etc.). Thus, it isnot intended that the present invention be limited to any particularrisk, nor is it intended that the present invention be limited to anyparticular disease.

As used herein, the term “suffering from disease” refers to a subject(e.g., a human) that is experiencing a particular disease or who hasbeen diagnosed has having a particular disease. It is not intended thatthe present invention be limited to any particular signs or symptoms,nor disease. Thus, it is intended that the present invention encompassessubjects that are experiencing any range of disease (e.g., fromsub-clinical manifestation to full-blown disease) wherein the subjectexhibits at least some of the indicia (e.g., signs and symptoms)associated with the particular disease.

As used herein, the terms “disease” and “pathological condition” areused interchangeably to describe a state, signs, and/or symptoms thatare associated with any impairment of the normal state of a livinganimal or of any of its organs or tissues that interrupts or modifiesthe performance of normal functions, and may be a response toenvironmental factors (such as emotional trauma, physical trauma,malnutrition, industrial hazards, or climate), to specific infectiveagents (such as worms, bacteria, or viruses), to inherent defect of theorganism (such as various genetic anomalies, or to combinations of theseand other factors.

As used herein, the terms “subject having AD” or “subject displayingsigns or symptoms or pathology indicative of AD” or “subjects suspectedof displaying signs or symptoms or pathology indicative of AD” refer toa subject that is identified or diagnosed as having or likely to have ADbased on known AD signs, symptoms and pathology.

As used herein, the terms “subject at risk of displaying pathologyindicative of AD” and “subject at risk of AD” refer to a subjectidentified as being at risk for developing AD.

As used herein, the term “AD therapeutic” refers to an agent used totreat or prevent AD. Such agents include, but are not limited to, smallmolecules, drugs, antibodies, pharmaceuticals, and the like.

As used herein, the term “cognitive function” generally refers to theability to think, reason, concentrate, or remember. Accordingly, theterm “decline in cognitive function” refers to the deterioration of lackof ability to think, reason, concentrate, or remember.

As used herein, the terms “modulate,” “modulates,” “modulated” or“modulation” shall have their usual meanings, and encompass the meaningsof the words “enhance,” “promote,” “increase,” “agonize,” “inhibit,”“decrease” or “antagonize.” A modulator of, e.g., an enzymatic activity,such as an activity of γ-secretase, may act directly, i.e., by directinteraction with the enzyme having the activity to be modulated, or itmay act indirectly, i.e., without direct interaction with the enzyme,but via a pathway that results in modulation of the activity.

As used herein, the term “assessing a subject for AD” refers toperforming one or more tests to determine, e.g., the presence orprogression of AD in a subject, or the risk of development of AD in asubject. Assessing a subject for AD and/or to distinguishing Alzheimer'sdisease from other causes of memory loss, may comprise evaluating one ormore of the following:

-   -   1. Medical history, comprising assessing a subject's general        health and past medical problems, problems a subject may have in        carrying out daily activities    -   2. Basic medical tests, comprising, e.g., blood tests to rule        out other potential causes of the dementia, such as thyroid        disorders or vitamin deficiencies.    -   3. Mental status evaluation, so, e.g., screen memory,        problem-solving abilities, attention spans, counting skills and        language.    -   4. Neuropsychological testing, comprising more extensive        assessment of memory, problem-solving abilities, attention        spans, counting skills and language.    -   5. Brain scans or imaging, using, e.g., computerized tomography        (CT magnetic resonance imaging (MM); and a positron emission        tomography (PET) to look for visible abnormalities.

As used herein, an “agonist” is any compound that acts directly orindirectly on a molecule to produce a pharmacological effect, while an“antagonist” is any compound that acts directly or indirectly on amolecule to reduce a pharmacological effect.

The terms “sample” and “specimen” are used in their broadest sense andencompass samples or specimens obtained from any source. As used herein,the term “sample” is used to refer to biological samples obtained fromanimals (including humans), and encompasses fluids, solids, tissues, andgases. In some embodiments of the invention, biological samples includeneural tissue (e.g., brain tissue) cerebrospinal fluid (CSF), serousfluid, urine, saliva, blood, and blood products such as plasma, serumand the like. However, these examples are not to be construed aslimiting the types of samples that find use with the present invention.

As used herein, the term “blood-brain barrier” refers a structure in thecentral nervous system (CNS) that restricts the passage of variouschemical substances and microscopic objects (e.g. bacteria) between thebloodstream and the neural tissue. Directional references to “inside”and “outside” the blood-brain barrier refer to things on thebrain/neural tissue side of blood-brain barrier, or the non-brain/neuralside of the blood-brain barrier, respectively.

As used herein, the term “blood-brain barrier impermeable variant” asused in reference to a material or compound (e.g., a drug) refers to avariant of a compound having reduced ability to penetrate theblood-brain barrier when administered peripherally to a subject, compareto the penetrability of a parent or reference compound, such that, e.g.,the variant does not substantially penetrate the blood-brain barrier ofthe subject to whom it is administered. As discussed below, the abilityof a compound to cross the blood-brain barrier may be characterized anyof a number of methods known in the art, e.g., by in vivo or in vitrotesting, by computational modeling, or by characterization of a compound(e.g., by physical testing or computational modeling) with respect tofeatures linked to blood-brain barrier transmissibility, e.g., size,charge, etc.

Methods of determining or estimating brain/CNS uptake of drugs includein vivo methods (e.g., intravenous or carotid injection followed bybrain sampling or imaging), in vitro methods using, e.g., isolated brainmicrovessels or cell culture models, and computational (in silico)prediction methods, typically based on factors such as molecular weightand lipophilicity. See, for example, U. Bickel, NeuroRx. 2005 January;2(1): 15-26, which is incorporated herein by reference, for a review andcomparison of methods of measuring drug transport across the blood-brainbarrier.

The lipophilicity/hydrophilicity of a compound are generally associatedwith the rate and extent of entry of a compound into the brain. Thelipophilicity/hydrophilicity of a drug is often represented as apartition coefficient representing the behavior of a drug whenpartitioned in an immiscible organic/aqueous solvent system. An1-octanol/water partition system has been used extensively in assessingthe capability of compounds to cross the blood-brain barrier. The1-octanol/water partition coefficient, “log P,” has been in longstanding use as a descriptor of lipophilicity, and computer algorithmsproviding calculated log P values, like Clog P and Mlog P, often closelymatch experimentally measured values (within about 0.3 log units;Bickel, supra). For ionizable molecules, the distribution coefficients,i.e., log P values at a defined pH (typically the physiological plasmapH of 7.4) are used. If log P and pKa are known, log D (log distributioncoefficient) may be derived using the Henderson-Hasselbalch equation.Log D at pH 7.4 is often quoted to give an indication of thelipophilicity of a drug at the pH of blood plasma.

Hansch and coworkers have determined that drugs with a log P of about 2will generally find ready entry into the central nervous system (Hanschet al., 1987, J. Pharm. Sci. 76(9):663-687, incorporated herein byreference), and that drugs that are more hydrophilic, such that theyhave low log P values (e.g., about 1) generally have decreased abilityto enter the CNS. This observation has been applied to the modificationof drugs to reduce CNS penetration as a means of controlling, e.g.,CNS-toxicity or side effects. For example the CNS penetration of heartdrug, ARL-57. This drug was considered to be an excellent cardiotonicdrug but which could not be used in patients because it caused“spectacular bright color vision” in humans. ARL-57 has a log P=2.59 atpH 8. A more hydrophilic variant of the substance, ARL115, (sulmazole;log P=1.17 at pH 8; calcd. 1.82) was produced and found to lack the CNSside effects, demonstrating that modification oflipophilicity/hydrophilicity can be used as a means of altering, e.g.,reducing) drug penetration of the blood-brain barrier (Hansch, et al.,supra).

The partition coefficient (log P) of imatinib mesylate has beencalculated to be 1.198 and 1.267 at 25 and 37° C., respectively(Velpandian, et al., Journal of Chromatography B, 804(2):431-434(2004)). This log P value is consistent with the data showing thatimatinib does not substantially penetrate the blood-brain barrier.

The terms “peripheral” and “periphera” as used in reference to alocation in or on, or a tissue of a subject refer to all locations andtissues of the subject that are outside of the blood-brain barrier.

As used herein, the phrase “does not substantially cross the blood brainbarrier” or “does not substantially penetrate the blood brain barrier”relates to material or compounds, e.g., GLEEVEC imatinib mesylate(STI-571) that, if administered in a peripheral tissue or taken orally,either remain absent from a CNS sampling (e.g., in brain tissue,cerebrospinal fluid) altogether, or are present in the CNS sampling at asmall percentage of the concentration found in the peripheral tissue,e.g., less than about 10%, preferably less than about 5%, and morepreferably less than about 2% of the concentration found in peripheraltissues. For example, GLEEVEC/STI-571 has poor penetration of theblood-brain barrier, as shown in a STI-571-treated leukemia patientwhose cerebral spinal fluid (CSF) level of the drug was 92-fold lowerthan in the blood (Takayama N, Sato N, O'Brien S G, Ikeda Y, Okamoto S.Br J Haematol. 119:106-108, 2002). Thus, GLEEVEC/STI-571 imatinibmesylate does not substantially penetrate the blood brain barrier.

As used herein, the term “effective amount” refers to the amount (e.g.,of a composition comprising a modulator of γ-secretase activity of thepresent invention) sufficient to produce a selected effect. An effectiveamount can be administered in one or more administrations, applicationsor dosages and is not intended to be limited to a particular formulationor administration route.

As used herein, a “sufficient amount” of a compound, or “an amount of acompound sufficient to . . . ” refers to an amount that contains atleast the minimum amount necessary to achieve the intended result. Suchan amount can routinely be determined by one of skill in the art basedon data from studies using methods of analysis such as those disclosedherein.

As used herein, the term “about” means within 10 to 15%, preferablywithin 5 to 10%.

As used herein, the terms “manage,” “managing” and “management” refer tothe beneficial effects that a subject derives from a compound, such as acompound that lowers Aβ levels exhibited by a cell or tissue, which doesnot result in a cure of the disease. In certain embodiments, a subjectis administered one or more such agents to “manage” a disorder so as toprevent or slow the progression or worsening of the disorder.

As used herein, the terms “prevent”, “preventing” and “prevention” referto the impedition of the recurrence or onset of an Aβ-related disorderor one or more symptoms of a Aβ-related disorder in a subject.

As used herein, a “protocol” includes dosing schedules and dosingregimens. The protocols herein are methods of use and includeprophylactic and therapeutic protocols.

As used herein, the terms “administration” and “administering” refer tothe act of giving a drug, prodrug, or other agent, or therapeutictreatment (e.g., compositions of the present invention) to a subject(e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, andorgans). Exemplary routes of administration to the human body can bethrough the eyes (ophthalmic), mouth (oral), skin (topical ortransdermal), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear,rectal, vaginal, by injection (e.g., intravenously, subcutaneously,intratumorally, intraperitoneally, etc.) and the like. “Peripheraladministration” refers to any route of administration that is givenoutside the blood-brain barrier.

As used herein, the terms “co-administration” and “co-administering”refer to the administration of at least two agent(s) (e.g., compositionscomprising STI-571, N-desmethyl imatinib, imatinibpara-diaminomethylbenzene, and one or more other agents—e.g., anAβ-related disease therapeutic) or therapies to a subject. In someembodiments, the co-administration of two or more agents or therapies isconcurrent. In other embodiments, a first agent/therapy is administeredprior to a second agent/therapy. Those of skill in the art understandthat the formulations and/or routes of administration of the variousagents or therapies used may vary. The appropriate dosage forco-administration can be readily determined by one skilled in the art.In some embodiments, when agents or therapies are co-administered, therespective agents or therapies are administered at lower dosages thanappropriate for their administration alone. Thus, co-administration isespecially desirable in embodiments where the co-administration of theagents or therapies lowers the requisite dosage of a potentially harmful(e.g., toxic) agent(s), and/or when co-administration of two or moreagents results in sensitization of a subject to beneficial effects ofone of the agents via co-administration of the other agent.

As used herein, the terms “treat” and “treating” includes administeringtherapy to prevent, cure, or alleviate/prevent the symptoms associatedwith, a specific disorder, disease, injury or condition.

As used herein, the term “treatment” or grammatical equivalentsencompasses the improvement and/or reversal of the symptoms of disease(e.g., an Aβ-related disease, such as Alzheimer's disease). A compoundthat causes an improvement in any parameter associated with disease whenused in the screening methods of the instant invention may thereby beidentified as a therapeutic compound. The term “treatment” refers toboth therapeutic treatment and prophylactic or preventative measures.For example, those who may benefit from treatment with compositions andmethods of the present invention include those already with a diseaseand/or disorder (e.g., an Aβ-related disease, or symptoms or pathologiesconsistent with an Aβ-related disease) as well as those in which adisease and/or disorder is to be prevented (e.g., using a prophylactictreatment of the present invention).

The term “compound” refers to any chemical entity, pharmaceutical, drug,and the like that can be used to treat or prevent a disease, illness,sickness, or disorder of bodily function. As used herein, a compound maybe a single composition (e.g., a pure preparation of a chemical) or itmay be a composition comprising a plurality of chemicals (e.g., one ormore effective agents and one or more inert agents). A compound maycomprise both known and potential therapeutic compositions. A compoundcan be determined to be therapeutic by screening using the screeningmethods of the present invention.

A “known therapeutic” compound or agent includes a therapeutic compoundthat has been shown (e.g., through animal trials or prior experiencewith administration to humans) to have a therapeutic effect in atreatment. However, a known therapeutic compound is not limited to acompound having a particular level of effectiveness in the treatment orprevention of a disease (e.g., an Aβ-related disease), and includes,e.g., compounds for which data suggests that there is some beneficialeffect and little or no negative effect (e.g., compounds that aregenerally recognized as safe, such as food extracts and nutraceuticalcompounds). Examples of known therapeutic agents for treating,ameliorating, or reducing risk or severity of Aβ-related diseases (e.g.Alzheimer's disease) when used alone or in combination with othercompounds or therapies include, but are not limited to cannabinoids(see, e.g., Ramirez, et al, The Journal of Neuroscience, Feb. 23, 2005,25(8):1904-1913); dimebom (see, e.g., R S Doody, et al., The Lancet372:207-215 (2008); anti-inflammitory agents such as prednisone (asteroid) and non-steroidal anti-inflammatory drugs (NSAIDs), includingbut not limited to ibuprofen, naproxyn, indomethacin;cholesterol-lowering and/or heart protective drugs such as statins,e.g., atorvastatin (LIPITOR®), cerivastatin (BAYCOL®), fluvastatin(e.g., LESCOL®), mevastatin, pitavastatin (e.g., LIVALO®), pravastatin(e.g., PRAVACHOL®), rosuvastatin (e.g., CRESTOR®) and simvastatin (e.g.,ZOCOR®); Selective estrogen receptor molecules (SERMs), e.g., raloxifene(EVISTA®); antihypertensives, including alpha-blockers, beta-blockers,alpha-beta blockers, angiotensin-converting enzyme inhibitors,angiotensin receptor blockers (ARBs, such as valsartan (e.g., DIOVAN®)),calcium channel blockers, and diuretics (see, e.g., I Hajjar, et al, TheJournals of Gerontology Series A: Biological Sciences and MedicalSciences 60:67-73 (2005)); and antioxidants such as garlic extract,curcumin, melatonin, resveratrol, Ginkgo biloba extract, green tea,vitamin C and vitamin E (see, e.g., B Frank, et al., Ann Clin Psychiatry17(4):269-86 (2005).

As used herein, the term “small molecule” generally refers to a moleculeof less than about 10 kDa molecular weight, including but are notlimited to natural or synthetic organic or inorganic compounds,peptides, (poly)nucleotides, (oligo)saccharides and the like. Smallmolecules specifically include small non-polymeric (i.e., not peptide orpolypeptide) organic and inorganic molecules.

As used herein the term “extract” and like terms refers to a process ofseparating and/or purifying one or more components from their naturalsource, or when used as a noun, refers to the composition produced bysuch a process.

As used herein, the term “kit” refers to any delivery system fordelivering materials. In the context of kinase activity or inhibitionassays, such delivery systems include systems that allow for thestorage, transport, or delivery of reaction reagents and/or supportingmaterials (e.g., buffers, written instructions for performing the assayetc.) from one location to another. For example, kits include one ormore enclosures (e.g., boxes) containing the relevant reaction reagentsand/or supporting materials. As used herein, the term “fragmented kit”refers to delivery systems comprising two or more separate containersthat each contains a subportion of the total kit components. Thecontainers may be delivered to the intended recipient together orseparately. For example, a first container may contain an enzyme for usein an assay, while a second container contains standards for comparisonto test compounds. The term “fragmented kit” is intended to encompasskits containing Analyte Specific Reagents (ASR's) regulated undersection 520(e) of the Federal Food, Drug, and Cosmetic Act, but are notlimited thereto. Indeed, any delivery system comprising two or moreseparate containers that each contains a subportion of the total kitcomponents are included in the term “fragmented kit.” In contrast, a“combined kit” refers to a delivery system containing all of thecomponents of a reaction assay in a single container (e.g., in a singlebox housing each of the desired components). The term “kit” includesboth fragmented and combined kits.

As used herein, the term “toxic” refers to any detrimental or harmfuleffects on a subject, a cell, or a tissue as compared to the same cellor tissue prior to the administration of the toxicant.

As used herein, the term “pharmaceutically purified” refers to acomposition of sufficient purity or quality of preparation forpharmaceutical use.

As used herein, the term “purified” refers to a treatment of a startingcomposition to remove at least one other component (e.g., anothercomponent from a starting composition (e.g., plant or animal tissue, anenvironmental sample etc.), a contaminant, a synthesis precursor, or abyproduct, etc.), such that the ratio of the purified component to theremoved component is greater than in the starting composition.

As used herein, the term “pharmaceutical composition” refers to thecombination of an active agent (e.g., composition comprising a modulatorof γ-secretase activity) with a carrier, inert or active, making thecomposition especially suitable for diagnostic or therapeutic use invitro, in vivo or ex vivo.

The terms “pharmaceutically acceptable” or “pharmacologicallyacceptable,” as used herein, refer to compositions that do notsubstantially produce adverse reactions, e.g., toxic, allergic, orimmunological reactions, when administered to a subject.

As used herein, the term “pharmaceutically acceptable carrier” refers toany of the standard pharmaceutical carriers including, but not limitedto, phosphate buffered saline solution, water, emulsions (e.g., such asan oil/water or water/oil emulsions), and various types of wettingagents, any and all solvents, dispersion media, coatings, sodium laurylsulfate, isotonic and absorption delaying agents, disintrigrants (e.g.,potato starch or sodium starch glycolate), and the like. Thecompositions also can include stabilizers and preservatives. Forexamples of carriers, stabilizers and adjuvants. (See e.g., Martin,Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton,Pa. (1975), incorporated herein by reference).

As used herein, the term “pharmaceutically acceptable salt” refers toany salt (e.g., obtained by reaction with an acid or a base) of acompound of the present invention that is physiologically tolerated inthe target subject (e.g., a mammalian subject, and/or in vivo or exvivo, cells, tissues, or organs). “Salts” of the compounds of thepresent invention may be derived from inorganic or organic acids andbases. Examples of acids include, but are not limited to, hydrochloric,hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric,glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric,acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic,malonic, sulfonic, naphthalene-2-sulfonic, benzenesulfonic acid, and thelike. Other acids, such as oxalic, while not in themselvespharmaceutically acceptable, may be employed in the preparation of saltsuseful as intermediates in obtaining the compounds of the invention andtheir pharmaceutically acceptable acid addition salts.

Examples of bases include, but are not limited to, alkali metal (e.g.,sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides,ammonia, and compounds of formula NW₄ ⁺, wherein W is C₁₋₄ alkyl, andthe like.

Examples of salts include, but are not limited to: acetate, adipate,alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate,citrate, camphorate, camphorsulfonate, cyclopentanepropionate,digluconate, dodecyl sulfate, ethanesulfonate, fumarate,flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate,chloride, bromide, iodide, 2-hydroxyethanesulfonate, lactate, maleate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate,pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate,succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like.Other examples of salts include anions of the compounds of the presentinvention compounded with a suitable cation such as Na⁺, NH₄ ⁺, and NW₄⁺ (wherein W is a C₁₋₄ alkyl group), and the like. For therapeutic use,salts of the compounds of the present invention are contemplated asbeing pharmaceutically acceptable. However, salts of acids and basesthat are non-pharmaceutically acceptable may also find use, for example,in the preparation or purification of a pharmaceutically acceptablecompound.

For therapeutic use, salts of the compounds of the present invention arecontemplated as being pharmaceutically acceptable. However, salts ofacids and bases that are non-pharmaceutically acceptable may also finduse, for example, in the preparation or purification of apharmaceutically acceptable compound. In some embodiments of the presentinvention, a medicament composition comprises a form selected from thegroup consisting of powder, solution, emulsion, micelle, liposome, gel,and paste form. In some embodiments, a medicament composition comprisesa tablet or a filled capsule, wherein said tablet or filled capsuleoptionally comprises an enteric coating material.

As used herein, the term “excipient” refers to an inactive ingredient(i.e., not pharmaceutically active) added to a preparation of an activeingredient.

The term “gene” refers to a nucleic acid (e.g., DNA) sequence thatcomprises coding sequences necessary for the production of apolypeptide, precursor, or RNA (e.g., rRNA, tRNA). The polypeptide canbe encoded by a full length coding sequence or by any portion of thecoding sequence so long as the desired activity or functional properties(e.g., enzymatic activity, ligand binding, signal transduction,immunogenicity, etc.) of the full-length or fragment are retained. Theterm also encompasses the coding region of a structural gene and thesequences located adjacent to the coding region on both the 5′ and 3′ends for a distance of about 1 kb or more on either end such that thegene corresponds to the length of the full-length mRNA. Sequenceslocated 5′ of the coding region and present on the mRNA are referred toas 5′ non-translated sequences. Sequences located 3′ or downstream ofthe coding region and present on the mRNA are referred to as 3′non-translated sequences. The term “gene” encompasses both cDNA andgenomic forms of a gene. A genomic form or clone of a gene contains thecoding region interrupted with non-coding sequences termed “introns” or“intervening regions” or “intervening sequences.” Introns are segmentsof a gene that are transcribed into nuclear RNA (hnRNA); introns maycontain regulatory elements such as enhancers. Introns are removed or“spliced out” from the nuclear or primary transcript; introns thereforeare absent in the messenger RNA (mRNA) transcript. The mRNA functionsduring translation to specify the sequence or order of amino acids in anascent polypeptide.

As used herein, the terms “gene expression” and “expression” refer tothe process of converting genetic information encoded in a gene into RNA(e.g., mRNA, rRNA, tRNA, or snRNA) through “transcription” of the gene(i.e., via the enzymatic action of an RNA polymerase), and, for proteinencoding genes, into protein through “translation” of mRNA. Geneexpression can be regulated at many stages in the process.“Up-regulation” or “activation” refer to regulation that increasesand/or enhances the production of gene expression products (e.g., RNA orprotein), while “down-regulation” or “repression” refer to regulationthat decrease production. Molecules (e.g., transcription factors) thatare involved in up-regulation or down-regulation are often called“activators” and “repressors,” respectively.

In addition to containing introns, genomic forms of a gene may alsoinclude sequences located on both the 5′ and 3′ end of the sequencesthat are present on the RNA transcript. These sequences are referred toas “flanking” sequences or regions (these flanking sequences are located5′ or 3′ to the non-translated sequences present on the mRNAtranscript). The 5′ flanking region may contain regulatory sequencessuch as promoters and enhancers that control or influence thetranscription of the gene. The 3′ flanking region may contain sequencesthat direct the termination of transcription, post-transcriptionalcleavage and polyadenylation.

The term “wild-type” refers to a gene or gene product isolated from anaturally occurring source. A wild-type gene is that which is mostfrequently observed in a population and is thus arbitrarily designed the“normal” or “wild-type” form of the gene. In contrast, the term“modified” or “mutant” refers to a gene or gene product that displaysmodifications in sequence and or functional properties (i.e., alteredcharacteristics) when compared to the wild-type gene or gene product. Itis noted that naturally occurring mutants can be isolated; these areidentified by the fact that they have altered characteristics (includingaltered nucleic acid sequences) when compared to the wild-type gene orgene product.

As used herein, the terms “nucleic acid molecule encoding,” “DNAsequence encoding,” and “DNA encoding” refer to the order or sequence ofdeoxyribonucleotides along a strand of deoxyribonucleic acid. The orderof these deoxyribonucleotides determines the order of amino acids alongthe polypeptide (protein) chain. The DNA sequence thus codes for theamino acid sequence.

As used, the term “eukaryote” refers to organisms distinguishable from“prokaryotes.” It is intended that the term encompass all organisms withcells that exhibit the usual characteristics of eukaryotes, such as thepresence of a true nucleus bounded by a nuclear membrane, within whichlie the chromosomes, the presence of membrane-bound organelles, andother characteristics commonly observed in eukaryotic organisms. Thus,the term includes, but is not limited to such organisms as fungi,protozoa, and animals (e.g., humans).

As used herein, the term “in vitro” refers to an artificial environmentand to processes or reactions that occur within an artificialenvironment. In vitro environments can consist of, but are not limitedto, test tubes and cell culture. The term “in vivo” refers to thenatural environment (e.g., an animal or a cell) and to processes orreaction that occur within a natural environment.

The terms “test compound” and “candidate compound” refer to any chemicalentity, pharmaceutical, drug, and the like that is a candidate for useto treat or prevent a disease, illness, sickness, or disorder of bodilyfunction (e.g., cognitive function, amyloid-associated disorder,circulation, hypertension, heart disease, etc.). Test compounds compriseboth known and potential therapeutic compounds. A test compound can bedetermined to be therapeutic by screening using the screening methods ofthe present invention.

As used herein, a “functional” molecule is a molecule in a form in whichit exhibits a property by which it is characterized. By way of example,a functional enzyme is one which exhibits the characteristic catalyticactivity by which the enzyme is characterized.

As used herein the term “antisense oligonucleotide” refers to a nucleicacid, e.g., an RNA or DNA segment, that is complementary to the sequenceof a target RNA (or fragment thereof). Typically, the target RNA is anmRNA expressed by a cell.

As used herein the term “interfering oligonucleotide” relates to anoligonucleotide capable of inhibiting the function of a target geneproduct, regardless of the mechanism of inhibition. As used herein,interfering oligonucleotides include but are not limited to antisenseoligonucleotides, aptamers, microRNAs (miRNAs), short interfering RNAs(siRNAs) and short hairpin RNAs (shRNAs) Short interfering RNAstypically consist of double-stranded RNA molecules, generally 19-22 nt,while short hairpin RNA, consists of palindromic sequences connected byloop sequences generally 19-29 nt. Methods of producing interferingoligonucleotides are well known to those of skill in the art, andinclude but are not limited to chemical synthesis, recombinant DNAtechniques or generation from larger precursor molecule using enzymaticcleavage, e.g., by Dicer enzymes.

As used herein, the term “antibody” refers to an immunoglobulin orimmunoglobulin-derived protein comprising an antigen recognition site.Antibodies include but are not limited to natural or recombinantimmunoglobulins comprising two heavy chains and two light chains, aswell as modified forms, including, e.g., fragment antibodies and singlechain antibodies comprising different combinations of portions of theheavy and light chains. The term encompasses polyclonal and monoclonalantibodies.

As used herein, the term “reduced kinase inhibition imatinib derivative”refers imatinib related compounds having decreased protein kinaseactivity compared to imatinib, e.g., imatinib para-diaminomethylbenzeneand N-desmethyl imatinib. These imatinib derivatives need not be derivedfrom imatinib as a starting material, and the term encompasses, e.g.,variants of imatinib that are produced by chemical synthesis.

DETAILED DESCRIPTION OF THE INVENTION

Particular embodiments of the invention are described in this DetailedDescription of the Invention, and in the Summary of the Invention, whichis incorporated here by reference. Although the invention has beendescribed in connection with specific embodiments, it should beunderstood that the invention as claimed should not be unduly limited tosuch specific embodiments. For example, the methods and compositions ofthe present invention are described in connection with particularmodulators of γ-secretase activity, e.g., GLEEVEC (STI-571) imatinibmesylate, and particular brain amyloid disorders (e.g., Alzheimer'sDisease). It should be understood that the present invention is notlimited to methods or compositions using or comprising imatinibmesylate, or to AD. The present invention relates to the use of reducedkinase inhibition imatinib derivatives in the treatment of Aβ-relateddisorders.

The present invention is based, in part, on Applicants' surprisingdiscoveries that modulation of Aβ expression or accumulation inperipheral tissues, e.g., in liver, provides therapeutic effect inAβ-linked diseases of the brain, e.g., Alzheimer's Disease. The presentinvention, therefore, relates, generally, to methods and compositionsfor preventing or treating a brain Aβ-related disorder, such as AD, viaadministration of compounds that modulate the production and/oraccumulation of Aβ in non-neural (i.e., peripheral) cells, fluids,and/or tissues.

As discussed above, amyloid-β (Aβ) peptides are metabolites of theamyloid precursor protein (APP), and are believed to be the majorpathological determinants of Alzheimer's disease (AD). APP isproteolyzed by and γ-secretase to produce Aβ peptides, with a 42-residueform of Aβ thought to be the most pathogenic. β-secretase is needed forhealthy brain function and thus is a poor candidate for inhibition as ameans of reducing Aft A number of brain-penetrant γ-secretase inhibitorshave shown undesirable side-effects as a result of disruptingγ-secretase action on other targets, in particular, the Notch family oftransmembrane receptors. One class of compounds has been found to reduceAβ production without affecting Notch signaling. This class of compoundsincludes the tyrosine kinase inhibitor imatinib mesylate (STI-571, tradename GLEEVEC) and the related compound,6-(2,6-dichlorophenyl)-8-methyl-2-(methylsulfanylphenyl-amino)-8H-pyrido[2,3-d]pyrimidin-7-one,referred to as inhibitor 2 (Netzer W J, et al., Proc Natl Acad Sci USA.100:12444-12449, 2003). However, this class of compounds has beendismissed as a treatment of brain Aβ disorders because it does not crossthe blood-brain barrier and is thus prohibitively difficult to deliverto brain tissue.

As noted above, we have discovered that modulation of Aβ production oraccumulation in peripheral tissues, e.g., in liver, provides therapeuticeffect in Aβ-linked diseases of the brain, e.g., Alzheimer's Disease.The present invention provides methods, compositions and processesrelated to treatment or prevention of AD by treating the liver of asubject. In particular, the present invention relates to altering Aβproduction, processing, accumulation or transport in the liver of asubject by direct inhibition of production (e.g., by inhibition ofexpression of APP), or by modulating a factor that in turn modulatesproduction, processing, accumulation or transport of Aβ in liver. Inpreferred embodiments, the inhibition is through the use of compoundsthat do not substantially cross the blood-brain barrier. In particularlypreferred embodiments, compositions and method for treatment comprisethe use of a STI-571 or a pharmaceutically acceptable salt thereof,administered peripherally, e.g., orally. In further particularlypreferred embodiments, compositions and method for treatment comprisethe use of an reduced kinase inhibition imatinib derivative or apharmaceutically acceptable salt thereof, administered peripherally,e.g., orally. In yet further preferred embodiments, the imatinibderivative is selected from the group consisting of N-desmethyl imatiniband an imatinib para-diaminobenzene composition such as atrihydrochoride.

Use of a Composition in the Manufacture of Medicaments

Imatinib is the generic name [International Non-proprietary Name] forthe compound4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamideof the following formula I:

STI-571 generally refers to the mesylate salt of imatinib, and has beenapproved for the treatment of chronic myeloid leukemia andgastrointestinal stromal tumors. The use of imatinib in the treatment ofbreast cancer is described in WO 2004/032925. Imatinib, its manufacture,its pharmaceutically acceptable salts, e.g. acid addition salts, and itsprotein kinase inhibiting properties are described in U.S. Pat. No.5,521,184, which is hereby incorporated by reference. “Imatinib”corresponds to4-(4-methylpiperazin-1-ylmethyl)-N[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamideas either free base or mesylate salt. The preparation of imatinib andthe use thereof are described in Example 21 of European patentapplication EP-A-0 564 409, which is hereby incorporated by reference.

N-desmethyl imatinib, also referred to as N-demethylated piperazinederivate of imatinib is an active metabolite of imatinib having thestructure shown in FIG. 10A.

Imatinib para-diaminomethylbenzene is a variant having the structureshown in FIG. 10B.

While peripheral administration is not limited to any particular routeof administration, in some preferred embodiments, administration isoral. Thus, in some preferred embodiments, the present inventioncomprises use of STI-571 and/or a reduced kinase inhibition imatinibderivative in the preparation of an orally administered medicament forthe treatment or prevention of a brain Aβ disorder. In some embodiments,the orally administered form comprises a tablet, while in someembodiments, an orally administered form comprises a capsule.

In preferred embodiments, the present invention comprises preparation ofa tablet or capsule comprising an effective amount of imatinib and/orreduced kinase inhibition imatinib derivative to reduce Aβ levels inbrain. For example, a capsule or tablet may comprise 100 to 1000 mg ofan active agent (e.g., imatinib or a derivative thereof). For example, atablet or capsule may comprise 100, 200, 300, 400, 500, 600, 700, 800,900, or 1000 mgs, or any convenient dosage amount in between (e.g., 125mgs, 150 mgs, 175 mgs, 225 mgs, 250 mgs . . . 975 mgs, etc.). In someembodiments, a tablet or capsule is configured to contain a smallereffective dose of imatinib or a reduced kinase inhibition imatinibderivative, e.g., 1 to 5 mg (e.g., 1, 2, 3, 4 or 5 mgs, or a convenientfractional amount thereof), 6 to 10 mgs, 11 to 15 mgs, etc.

Compositions and formulations for oral administration include, forexample, powders or granules, suspensions or solutions in water ornon-aqueous media, capsules, sachets wafers, dissolvable strips, andtablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersingaids or binders may be desirable. In preferred embodiments, a tablet orcapsule (or other form of peripheral administration) is configured todeliver a dose of, or an amount equivalent to any whole integer mgamount between 1 and 1000 mg (e.g., 1, 2, 3, 4, etc.), or any fractionalmg amount between 1 and 1000 mg. In certain embodiments, a formulationmay comprise, e.g., a capsule filled with a mixture of the composition:

Imatinib mesylate (STI-571) 119.5 mgs (corresponding to 100 mg imatinibfree base Cellulose MK GR 92 mg Crospovidone XL 15 mg Aerosil 200 2 mgMagnesium stearate 1.5 mg 230 mg

In some embodiments, a capsule or tablet comprises an enteric coating.“Enteric” refers to the small intestine, therefore “enteric coating”generally refers to a coating that substantially prevents release of amedication before it reaches the small intestine. While not limiting theinvention to any particular mechanism of action, it is understood thatmost enteric coatings work by presenting a surface that is stable atacidic pH but breaks down rapidly at higher pH.

Compositions and formulations for parenteral administration may includesterile aqueous solutions that may also contain buffers, diluents andother suitable additives such as, but not limited to, carrier compoundsand other pharmaceutically acceptable carriers or excipients.

The pharmaceutical formulations of the present invention, which mayconveniently be presented in unit dosage form, may be prepared accordingto conventional techniques well known in the pharmaceutical industry.Such techniques include the step of bringing into association the activeingredients with the pharmaceutical carrier(s) or excipient(s). Ingeneral the formulations are prepared by uniformly and intimatelybringing into association the active ingredients with liquid carriers orfinely divided solid carriers or both, and then, if necessary, shapingthe product.

The pharmacokinetics of imatinib mesylate (GLEEVEC) have been evaluatedin studies in healthy subjects and in population pharmacokineticstudies. Imatinib is well absorbed after oral administration, withC_(max) achieved within 2-4 hours post-dose. Mean absolutebioavailability is 98%. Following oral administration in healthyvolunteers, the elimination half-lives of imatinib and its major activemetabolite, the N-desmethyl derivative, are approximately 18 and 40hours, respectively. Mean imatinib AUC (Area under the plasma drugconcentration versus time curve) increases proportionally withincreasing doses ranging from 25 mg-1000 mg. There is no significantchange in the pharmacokinetics of imatinib on repeated dosing, andaccumulation is 1.5-2.5 fold at steady state when dosed once daily. Atclinically relevant concentrations of imatinib, binding to plasmaproteins in in vitro experiments is approximately 95%, mostly to albuminand al-acid glycoprotein. See, e.g., “Gleevec Prescribing Information”2003 revision T2003-09; Printed in U.S.A. 89019001 (Novartis).

CYP3A4 is the major enzyme responsible for metabolism of imatinib. Othercytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19,play a minor role in its metabolism. The main circulating activemetabolite in humans is the N-demethylated piperazine derivative,N-desmethyl imatinib, formed predominantly by CYP3A4. It shows in vitropotency similar to the parent imatinib. The plasma AUC for thismetabolite is about 15% of the AUC for imatinib.

Elimination is predominately in the feces, mostly as metabolites. Basedon the recovery of compound(s) after an oral 14C-labeled dose ofimatinib, approximately 81% of the dose was eliminated within 7 days, infeces (68% of dose) and urine (13% of dose). Unchanged imatinibaccounted for 25% of the dose (5% urine, 20% feces), the remainder beingmetabolites.

Typically, clearance of imatinib in a 50-year-old patient weighing 50 kgis expected to be 8 L/h, while for a 50-year-old patient weighing 100 kgthe clearance will increase to 14 L/h. However, the inter-patientvariability of 40% in clearance does not warrant initial dose adjustmentbased on body weight and/or age but indicates the need for closemonitoring for treatment related toxicity.

As in adult patients, imatinib was reportedly rapidly absorbed afteroral administration in pediatric patients, with a Cmax of 2-4 hours.Apparent oral clearance was similar to adult values (11.0 L/hr/m2 inchildren vs. 10.0 L/hr/m2 in adults), as was the half-life (14.8 hoursin children vs. 17.1 hr in adults). Dosing in children at both 260 mg/m2and 340 mg/m2 achieved an AUC similar to the 400-mg dose in adults. Thecomparison of AUC(0-24) on Day 8 versus Day 1 at 260 mg/m2 and 340 mg/m2dose levels revealed a 1.5 and 2.2-fold drug accumulation, respectively,after repeated once daily dosing. Mean imatinib AUC did not increaseproportionally with increasing dose. “Gleevec Prescribing Information”2003 revision T2003-09; Printed in U.S.A. 89019001 (Novartis).

Although modulation of Aβ production in liver by treatment with imatinibis used as an example above, the present invention is not limited totreatment of the liver with this compound, and provides general methodsof treating a subject for a brain Aβ disorder or predisposition to abrain Aβ disorder in a subject, comprising peripherally administering acompound that modulates expression of a gene in a peripheral tissue ofsaid subject. In preferred embodiments, modulation of said expression ofsaid gene results in modulation of Aβ production or accumulation in saidperipheral tissue. In certain preferred embodiments, the peripheraltissue is the liver of a subject.

In particularly preferred embodiments, the modulation of Aβ productioncomprises use of a composition that has reduced protein kinaseinhibition activity compared to, e.g., imatinib.

As described in Example 3, below, the present invention providescompositions that inhibit the formation of Aβ while exhibitingsubstantially reduced protein kinase inhibition compared to imatinib. Inparticular, present invention provides preparations of imatinibpara-diaminomethylbenzene and/or N-desmethyl imatinib for use in thereduction of Aβ loads in treated cell and subjects.

The present invention encompasses any method of influencing theproduction of Aβ in liver, including but not limited to alteringexpression and/or processing of APP. In some embodiments, the presentinvention provides methods comprising peripherally administering acompound that modulates expression of one or more of Psen 1, Apo E,InsP3R, Psen2, APP, Cib1, Ngrn, Zfhxlb, CLU (also known as ApoJ),PICALM, IDE, GSAP, and CR1 genes. In some embodiments, the methods ofthe present invention comprises peripherally administering a compoundthat modulates the activity of one or more of presenilin 2, calmyrin,neugrin, Zfhxlb, clusterin, phosphoinositol-binding clatherin assemblyprotein, complement component receptor 1, insulin degrading enzyme,GSAP, or APP expression or activity. In some embodiments, one or more ofthese genes or activities is modulated in the liver of a subject. Insome embodiments, modulation comprises inhibition of expression oractivity, while in some embodiments, modulation comprises stimulation ofexpression or activity.

Assessing and Monitoring Brain Aβ Disorders During Peripheral Treatment

The present invention relates to testing for and treatment of AD and ADrisk by testing of and administration to peripheral (i.e., non-brain)tissues of a subject. As discussed below, the present study demonstratesthat presenilin 2 expression in the liver and/or in one or moreperipheral tissues modifies Aβ accumulation, and that reduction of Aβ inthe periphery is sufficient to modify its deposition in the brain. Thus,despite extensive teaching in the literature to the contrary, aneffective therapeutic or prophylactic treatment for AD that reduces Aβaccumulation need not cross the blood-brain barrier and enter the brain.Inhibition of Psen2 or γ-secretase activity, or reduction of Aβproduction or accumulation by other means, outside of the centralnervous system (i.e., outside the blood-brain barrier) finds applicationin the protection of the brain from Aβ-related pathologies. Treatment ofperipheral tissues has the additional benefit of protecting the brainfrom any adverse side effects that could occur were the therapeutic toenter the brain.

In some embodiments, the present invention provides methods of tailoringtreatments to the biochemical status of a subject or patient. It iscontemplated that features of effective doses of one or more ofcompounds selected for the modulation of Aβ in a peripheral tissue maybe affected by the particular biochemical circumstances of a subject orpatient, including but not limited to the presence of other drugs ormedications (e.g. for treatment of an Aβ disorder or unrelatedconditions), or biochemical changes caused by other circumstances. Thepresent invention provides methods comprising monitoring a subject byassessing said subject for a brain Aβ disorder or progression of a brainAβ disorder before and after administration of a compound that modulatesproduction of Aβ, e.g., in liver. In some embodiments, therapy for abrain Aβ disorder is selected, adjusted, or altered accordingly.

EXPERIMENTAL EXAMPLES

The following examples are provided in order to demonstrate and furtherillustrate certain preferred embodiments and aspects of the presentinvention and are not to be construed as limiting the scope thereof.

Example 1 Identification of Modifiers of the Development of AD-LikePathology

Transgenic mouse models have been developed that recapitulate criticalfeatures of human Alzheimer's disease. The APP gene carrying some of thevariations that are AD-predisposing in humans have been joined tovarious transcriptional promoters and introduced into the mouse germline (Games D, Adams D, Alessandrini R, Barbour R, Berthelette P,Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Nature373:523-527; Hsia A Y, Masliah E, McConlogue L, Yu G Q, Tatsuno G, Hu K,Kholodenko D, Malenka R C, Nicoll R A, Mucke L. Proc Natl Acad Sci USA.96:3228-3233, 1999; Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y,Younkin S, Yang F, Cole G. Science 274:99-102, 1996; Sturchler-PierratC, Abramowski D, Duke M, Wiederhold K H, Mistl C, Rothacher S, LedermannB, Burki K, Frey P, Paganetti P A, Waridel C, Calhoun M E, Jucker M,Probst A, Staufenbiel M, Sommer B. Proc Natl Acad Sci USA94:13287-13292, 1997; Moechars D, Dewachter I, Lorent K, Reverse D,Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute C V, Checler F,Godaux E, Cordell B, Van Leuven F. J Biol Chem. 274:6483-6492, 1999;Richardson J C, Kendal C E, Anderson R, Priest F, Gower E, Soden P, GrayR, Topps S, Howlett D R, Lavender D, Clarke N J, Barnes J C, Haworth R,Stewart M G, Rupniak H T. Neuroscience 122:213-228, 2003; Buttini M, YuG Q, Shockley K, Huang Y, Jones B, Masliah E, Mallory M, Yeo T, Longo FM, Mucke L. J Neurosci. 22:10539-10548, 2002). The resulting transgenicmice develop Aβ deposits, but the timing varies from 3 months to 15months of age. The variables responsible for these age differencesinclude the particular transcriptional promoter chosen, the particularAD-predisposing mutations in the APP gene, the chromosomal site oftransgene integration and the mouse background strain on which thetransgene is perpetuated (reviewed in Bloom F E, Reilly J F, Redwine JM, Wu C C, Young W G, Morrison J H. Arch Neurol. 62:185-187, 2005).

One report (Kulnane L S, Lamb B T. Neurobiol Dis. 8:982-992, 2001)introduced R1.40, a human APP transgene carrying the so-called Swedishmutations (K670N, M671L, variations that predispose those humans thatinherit this mutated gene to develop early-onset AD) into a mixedC57Bl/6×129/Sv mouse genetic background. Expression of the R1.40transgene was driven from the natural human APP promoter. Aβ depositswere first detectable in brains of these mice at 14-16 months.Subsequently, the R1.40 transgene was crossed from its initialbackground separately into C57Bl/6 (B6), DBA/2 (D2) and 129/Svbackgrounds. Then, each of these 3 strains was bred to congeneity: 10 ormore back-crosses into the same background so that 3 transgenic strainswith uniform but distinct backgrounds were created (Lehman E J, KulnaneL S, Gao Y, Petriello M C, Pimpis K M, Younkin L, Dolios G, Wang R,Younkin S G, Lamb B T. Hum Mol Genet. 12:2949-2956, 2003). Although allthree transgenic strains produced the same amount of APP precursor(indicating that the transgene was expressed comparably in the 3 strainbackgrounds), B6s accumulated more Aβ (the pathogenic fragment of APP)as measured by ELISA on brain homogenates and plasma at 21 and 60 daysthan the other 2 strains, and developed amyloid deposits characteristicof human AD at 13.5 months, while the D2s were protected (no deposits at2 years). Thus, this indicates that there are genes that distinguish B6and D2 mice and that modify the development of AD-like pathology, andmost likely these are involved in the accumulation of the pathogenicsubstance Aβ (Lehman E J, Kulnane L S, Gao Y, Petriello M C, Pimpis K M,Younkin L, Dolios G, Wang R, Younkin S G, Lamb B T. Hum Mol Genet.12:2949-2956, 2003). The identities of the modifier genes might suggesttherapeutic or prophylactic modalities that would mimic the modifiereffect and delay or prevent the emergence of AD pathology. So as toassign the modifying genes to chromosomal intervals, Ryman andcolleagues (Ryman D, Gao Y, Lamb B T. Neurobiol Aging 29:1190-1198,2008) crossed female B6 R1.40 mice (homozygous for the transgene) withmale D2 R1.40 mice (also homozygous for the transgene), then crossedtheir F1 offspring (all of which had 2 copies of the R1.40 transgene) tonon-transgenic B6×D2 F1 offspring, generating 516 F2 mice, each of whichcarried a single transgene. These were genotyped with 909 SNPs. Aβ wasmeasured by ELISA in brain homogenates from the 516 mice. Regressionanalysis correlating the amount of Aβ accumulation with the genotypes ofthe 516 mice allowed 3 modifying loci to be assigned to broad regionscentered on the following positions: chromosome 1, 182.049374 Megabases(Mb); chromosome 2, 41.216315 Mb; chromosome 7, 63.680922 Mb.

Identifying a Modifier Gene

The mouse gene encoding presenilin 2, Psen2, is located on chromosome 1at 182.06371 Megabases, the center of the trait locus interval,suggesting it as a candidate for modifying Aβ accumulation and deposit.This is consistent with its function as a component of γ-secretase. ForPsen2 to represent the actual modifier mapped to chromosome 1 by Rymanand colleagues, its activity must vary heritably (in a Mendelianfashion) between B6 and D2 mouse strains, and the Psen2 activity must begreater in B6 mice than D2 mice, because lower γ-secretase activitywould be expected to be protective in AD. We investigated this issue bydetermining the amount of mRNA that accumulates from the Psen2 gene invarious tissues in B6 and D2 mouse strains and up to 89 strains ofrecombinant inbred mice produced by crossing B6 and D2 mice and breedingthe offspring to congeneity. The concentrations of each of more than20,000 mRNAs in 10 tissues (brain, cerebellum, liver, striatum, kidney,hippocampus, eye, prefrontal cortex, nucleus accumbens and neocortex) ofB6 and D2 mouse strains and the 89 recombinant inbred mouse strains areavailable in public databases compiled at http://www.GeneNetwork.org.For each of the 89 recombinant inbred mouse strains, it has beendetermined by genotyping whether the strain has inherited each intervalof its genome from the B6 or D2 parent.

Probe rs13476267 is located on chromosome 1 at 182.120454 Mb. Using thesoftware on the world wide web public site atgenenetwork.org/webqt1/WebQTL.py, we performed trait correlationsbetween the genotype of the rs13476267 interval and the amount of Psen2mRNA that accumulates in each of the 10 tissues in the up to 89recombinant inbred mice, calculating the Pearson's product-moment. Thevalues were:

$\begin{matrix}{brain} & {{r} < 0.05} \\{cerebellum} & {r = 0.6344} \\{liver} & {r = {- 0.9402}} \\{striatum} & {r = 0.5329} \\{kidney} & {r = {- 0.4733}} \\\begin{matrix}\begin{matrix}{hippocampus} \\{eye}\end{matrix} \\{{prefrontal}\mspace{14mu}{cortex}}\end{matrix} & {{\begin{matrix}r \\r \\r\end{matrix}}\begin{matrix}\begin{matrix}{< 0.36} \\{< 0.35}\end{matrix} \\{< 0.51}\end{matrix}} \\{{nucleus}\mspace{14mu}{cortex}} & {r = 0.7260} \\{neocortex} & {r = 0.5500}\end{matrix}$

None of the tissue samples derived from brain shows high heritability(|r|>0.9) of Psen2 expression, and for the two brain regions thatexhibit modest heritability of Psen2 mRNA expression, cerebellum andnucleus accumbens, more Psen2 mRNA was correlated with the D2 genotypethan the B6 genotype. Thus, Psen2 expression in the brain is not amodifier of Aβ accumulation. However, in the liver, the amount of Psen2mRNA was highly correlated with the genotype at the Psen2 locus (FIG.1A). Furthermore, B6 mice express more Psen2 mRNA than do D2 mice.

The data demonstrate that Psen2 expression in the liver or in one ormore peripheral tissues modifies Aβ accumulation, and that reduction ofAβ in the periphery is sufficient to modify its deposition in the brain.Thus, despite extensive teaching in the literature to the contrary,based at least in part on the natural assumption that a brain diseasewould be caused by events that occur within the brain, an effectivetherapeutic or prophylactic treatment for AD that reduces Aβaccumulation need not cross the blood-brain barrier and enter the brain.Inhibition of Psen2 or γ-secretase activity, or reduction of Aβproduction or accumulation by other means, outside of the centralnervous system, is sufficient to protect the brain from Aβ depositionwhile protecting the brain from adverse side effects that might occurwere the therapeutic to enter the brain. Treatment of Aβ accumulation inthe periphery can be accomplished by using routes of drug delivery thatdo not comprise direct application to the CNS (e.g., by CSF delivery),such as via oral administration.

Example 2 Peripheral Administration of STI-571 Imatinib Mesylate toReduce Aβ in Brain

The data from the mapping studies and our further ideas suggested anovel therapeutic route to treat AD (its initiation, progression orseverity) based on modulating Aβ production in liver. The basis of a newtherapeutic strategy is that a drug that lowers steady-state levels ofAβ in blood (by inhibiting production of Aβ in liver) would lower Aβconcentrations in the brain.

An experiment was designed to test the effect of STI-571 imatinibmesylate administration on Aβ protein levels in brain and blood tissuein 2 strains of mice. Mice were administered STI-571 imatinib mesylateby IP injection over the course of one week and brain and tissue samplesremoved and Aβ protein levels measured by ELISA or Western blot.

Wild-type C57Bl/6 and DBA/2J male mice (age 8-12 weeks) wereadministered drug or vehicle twice daily for 7 days by intraperitonealinjection. Vehicle groups (n=4 animals per strain) were injected with100 ul of saline and drug treatment groups (n=4) received 1, 10 or 100mg/kg STI-571 (GLEEVEC imatinib, methanesulfonate salt, Catalog No.1-5508, LC laboratories, Woburn, Mass.). The STI-571 dose prescribed forhuman cancer patients is 100 mg to 1000 mg. See, for example, GleevecPrescribing Information 2003 revision T2003-09; Printed in U.S.A.89019001 (Novartis), incorporated herein by reference.

Animals were sacrificed 12 hr after the last injection. Individual micewere anesthetized with isoflurane and blood samples (100-300 ul) takenby cardiac puncture with heparinized syringes. Samples were placed onice for 30 minutes in the presence of EDTA and then centrifuged for 20minutes at 16,000×g at 4° C. The plasma fraction was removed and storedat −80° C. Brains were removed and frozen rapidly on dry ice and storedat −80° C.

Detection of mouse Aβ₁₋₄₀ in blood and brain samples was performed byusing a commercially available immunoassay kit (Biosource mouse Aβ₁₋₄₀,Catalog No. KMB3481, Invitrogen, Carlsbad, Calif.) or by Western blot.Mouse brain samples were prepared by homogenizing brain tissue in apolytron in the presence of 5M guanidine HCl and 50 mM Tris HCl, pH 8.0as described in the assay protocol. (see, e.g., Masliah, E., et al.,(2001) β amyloid peptides enhance α-synuclein accumulation and neuronaldeficits in a transgenic mouse model linking Alzheimer's disease andParkinson's disease. PNAS 98:12245-12250; Johnson-Wood, K, et al. (1997)Amyloid precursor protein processing and A beta42 deposition in atransgenic mouse model of Alzheimer disease PNAS 94:1550-1555; andChishti, M. A., et al. (2001); Early-onset amyloid deposition andcognitive defects in transgenic mice expressing a double mutant form ofamyloid precursor protein 695. J. Biol. Chem. 276:21562-21570.)

For the assay, brain homogenates were diluted 1:10 in a reaction buffercontaining Dulbecco's phosphate buffered saline with 5% BSA and 0.03%Tween-20, supplemented with protease inhibitor cocktail (Catalog No.539131, EMD Biosciences, La Jolla, Calif.). Blood samples were diluted1:5 in standard diluent buffer. Samples were assayed in duplicate andOD450 measured on a Tecan infinite 2000 plate reader.

Oligomeric Aβ was extracted in the SDS fraction essentially as described(T. Kawarabayashi, et al., Neurosci 21, 372 (2001)). For Western blots,samples were subjected to PAGE analysis, transferred to PVDF membranesand the Aβ hexamers were visualized using a monoclonal antibody 4G8directed against mouse Aβ (1:1,000; Covance) using the manufacturer'srecommended protocol. Blots were scanned by densitometry, and thenreprobed with an antibody to histone H3 (1:50,000; Abcam) as a loadingand transfer control. Data are depicted as normalized optical density.

Levels of Aβ in both the brain and blood differed between the twostrains of mice (C57Bl/6 and DBA/2J) tested. The levels of Aβ werehigher in both brain and blood samples from C57Bl/6 mice compared toDBA/2J in the vehicle-treated control groups, as was shown previously.

FIG. 3 shows the effects of peripherally administered STI-571 on thelevels of Aβ in plasma and brain. FIG. 3A shows Western blots showinglevels of Aβ hexamers in plasma from young D2 mice treated with salinevehicle (lanes 1, 2, 9 and 10) or STI-571 at three doses: lanes 3, 4,11, and 12 show results with 1 mg/kg; lanes 5, 6, 13 and 14 show resultswith 10 mg/kg; and lanes 7, 8, 15 and 16 show results with 100 mg/kg;n=4 per group. FIG. 3B shows a bar graph quantification of the Westernblot images in FIG. 3A. FIG. 3C shows a Western blot showing levels ofAβ hexamers in brain extracts from young B6 mice treated with salinevehicle or STI-571 at 20 mg/kg (n=10 per group in total; only n=5 areshown in Western blot). FIG. 3D shows a bar graph quantification of theWestern blot images in FIG. 3C. FIGS. 3E and 3F show bar graphsindicating levels of Aβ hexamers in brain extracts (E) or plasma (F) ofold B6 mice treated with saline vehicle or STI-571 at 20 mg/kg (n=4 pergroup).

A dose-dependent reduction in plasma Aβ was observed (FIG. 3A-B), andthe highest dose reduced circulating Aβ by approximately 75%. Anintermediate dose, 20 mg/kg, was selected for study of brain effects.This dose reduced brain and plasma levels of Aβ by approximately 50% inyoung and old B mice (FIGS. 3B and 3C). These levels of Aβ have beenobserved to be protective in the R1.40 mouse model (E. J. Lehman, etal., Hum Mol Genet 12, 2949 (2003)).

These results demonstrate that short-term (one week) STI-571 imatinibmesylate treatment significantly lowers Aβ levels in the blood andbrain. Furthermore, as the drug does not cross the blood-brain barrierappreciably at the concentrations used in this study, the resultsindicate that STI-571 imatinib mesylate can indirectly alter brain Aβlevels by modulating Aβ production peripherally.

Example 3 Identification of Candidate Chromosome 2 and 7 Modifier Genes

The studies described above demonstrate that pathogenic Aβ likelyderives from the liver. Using the same database and methodologydescribed above, we also searched for genes that map into thechromosomes 2 and 7 intervals, and whose activities in the liver variedheritably between B6 and D2 mouse strains. Marker rs4226715 is locatedon chromosome 7 at 80.138616 Mb, within the modifier locus for thatchromosome. Two genes from this interval showed extremely highheritability of expression within the liver: the Ngrn gene, and the Cib1gene. The Ngrn gene encodes neugrin, a widely expressed protein ofunknown function whose expression increases in some cancers and has beenassociated with neuroblastoma differentiation (S. Ishigaki, et al.,Biochem Biophys Res Commun 279, 526 (2002), S. R. Hustinx, et al.,Cancer Biol Ther 3, 1254 (2004)), and the Cib1 gene, encodes calmyrin, amyristoylated calcium- and integrin-binding membrane-associated proteinoriginally discovered because of its preferential interaction withpresenilin 2 in HeLa cells (S. M. Stabler, et al., J Cell Biol 14, 145,1277 (1999)). These genes showed the highest correlations: Pearson'svalues r=0.945, and r=−0.913, respectively, both p<4.99 e-39, (FIGS. 5and 4, respectively). Ngrn is located on chromosome 7 at 80.138736 Mband Cib1 at 80.101507, both consistent with the mapped modifier locus.

As noted above, calmyrin has a demonstrated interaction with presenilin2. However, because the calmyrin distribution in the brain does notcorrelate well with either brain presenilin distribution or regions mostsusceptible to AD pathology, prior studies have considered its potentialrole in contributing to Aβ production in the forebrain, but judged sucha role unlikely (M. Blazejczyk, et al., Biochim Biophys Acta 1762, 66(2006)). Calmyrin is, however, highly expressed by the liver (S. M.Stabler, supra). One suggested calmyrin activity is as a protein ligandfor the inositol 1,4,5-trisphosphate receptor Ca(2+) release channel (C.White, et al., J Biol Chem 281, 20825 (2006).), whose gating activity isaberrant in chicken cells transfected with mutant presenilin genes (K.H. Cheung, et al., Neuron 58, 871 (2008)).

The heritability of liver calmyrin mRNA expression was extremely high.In every strain that inherited its Cib1 genes from the B6 parents, theamount of calmyrin mRNA was higher than the amount observed in strainsthat inherited their Cib1 genes from the D2 parents (FIG. 5A). Onestrain (line 73) appears to be heterozygous at the probe, but expressesD2-like amounts of calmyrin mRNA. This suggests that low calmyrinexpression in liver decreases the accumulation of Aβ in the brain, andprotects mice from its adverse effects.

Treatment with a compound that decreases the Aβ-potentiating activity ofcalmyrin should mimic the low expression of the D2 genotype andtherefore be protective.

Neugrin has an inverse correlation (FIG. 4). Abundance of neugrin inliver is correlated with lower Aβ accumulation, suggesting thattreatment with a compound that increases Neugrin should be protective.

Marker rs3669981 is located on chromosome 2 at 44.943029 Mb, within thefairly broad modifier locus for that chromosome. The Zfhxlb gene(44.810557 Mb), which encodes zinc finger homeobox 1b protein, showedthe highest correlation: r=−0.919, p=4.99 e-39 (FIG. 5B). The Zfhxblprotein is a Smad-interacting transcriptional corepressor involved inWnt and hedgehog signaling (G. Bassez, et al., Neurobiol Dis 15, 240(2004); G. Verstappen, et al., Hum Mol Genet 17, 1175 (2008); N.Isohata, et al., Int J Cancer 125, 1212 (2009).). Detrimental variantsof the gene cause the developmental disorder Mowat-Wilson syndrome,which presents with multiple congenital deficits including mentalretardation (C. Zweier, et al., Am J Med Genet 108, 177 (2002)).Although the Zfhxlb mRNA is widely expressed during development,especially within the nervous system, in the adult mouse it is mosthighly expressed in the liver (G. Bassez, supra). The Zfhxlb gene islocated on chromosome 2 at 44.810557 Mb, consistent with the mappedmodifier locus. The heritability of liver mRNA expression was extremelyhigh for this gene. In nearly every strain that inherited its Zfhxlbgenes from the B6 parents the amount of Zfhxlb mRNA was greater than instrains that inherited their Zfhxlb genes from the D2 parents (FIG. 5B).Strains 12 and 36 differed in genotype at the probe but had similar mRNAlevels. These data suggest that low Zfhxlb expression in liver lowersthe accumulation of Aβ in the brain and protects mice from its adverseeffects. Treatment with a compound that inhibits the activity of Zfhxlbshould mimic the low expression of the D2 genotype and therefore beprotective.

Example 3 Measurement of AD Inhibition by Imatinib DerivativeCompositions

Protocol

1. Thaw SY5Y-APP cells, add to warmed high glucose DMEM with 10% serum,pen-strep in t-75 flask. In 2 days, split culture into 4 flasks. Collectcells from 3 and freeze in liquid N2. Use remaining culture forexperiment.

2. Seed 24-well plate with cells in same media. Grow to confluence.

3. Prepare stock solutions of imatinib and desmethyl imatinib:

-   -   500 ug in 100 ul is 10 mM stock    -   Also make 1 mM stock        4. Replace media (1 ml) and add inhibitor (in DMSO vehicle) or        vehicle only, as follows:    -   1. vehicle only    -   2. 3 ul imatinib from 1 mM stock=3 uM final concentration    -   3. 3 ul desmethyl imatinib (Santa Cruz Biotechnology Cat. No.        SC-208027; Toronto Research Chemicals, Cat. No. D292045) from 1        mM stock=3 uM final concentration    -   4. 10 ul imatinib from 1 mM stock=10 uM final concentration    -   5. 10 ul desmethyl imatinib from 1 mM stock=10 uM final        concentration    -   6. 3 ul imatinib from 10 mM stock=30 uM final concentration    -   7. 3 ul desmethyl imatinib from 10 mM stock=30 uM final        concentration    -   8. 10 ul desmethyl imatinib from 10 mM stock=100 uM final        concentration        5. After 16 hr incubation, isolate media, add 10 ul protease        inhibitor and spin out cells and debris (3000×g);        4. Measure Aβ in 100 μL aliquot with Covance ELISA kit        SIG-38952, luminometer

The results are shown in FIG. 6. These data show that the metabolitedesmethyl imatinib (shown in FIG. 10A) produces more effective reductionof Aβ than does imatinib (Gleevec) when administered over the same rangeof concentration.

In addition to the above, the effect on Aβ concentration of threevariants of imatinib was tested as described above, except Aβ wasmeasured on 150 μL of media supernatant rather than 100 uL.

-   -   A. Imatinib (Gleevec) 3, 10, and 30 μM;    -   B. Imatinib para-diaminomethylbenzene 3 HCl (shown in FIG. 10B,        Toronto Research Chemicals, Cat. No. 1267995) at 3, 10, 30, and        100 μM;    -   C. imatinib (pyridine)-N-oxide (shown in FIG. 10C, Toronto        Research Chemicals, Cat. No. 1268010); and    -   D. imatinib (piperidine)-N-oxide (shown in FIG. 10D, Toronto        Research Chemicals, Cat. No. 1268000).

The results are shown in FIG. 7. These data show that active metaboliteImatinib para-diaminomethylbenzene 3 HCl (shown in FIG. 10B) producesstronger inhibition of Aβ than does imatinib (Gleevec) when administeredover the same range of concentration. These data also show that imatinib(pyridine)-N-oxide and imatinib (piperidine)-N-oxide have little or noeffect on Aβ concentration.

Example 4 Measurement of Inhibition of Abl Kinase by Imatinib-RelatedCompositions

The following were combined in order:

-   -   10 μL 2.5× kinase assay buffer    -   2.5 μL Abl kinase (Millipore, Temecula, Calif.)    -   1 μL DMSO vehicle or inhibitor in DMSO on ice    -   10 μL gamma ³²P-ATP    -   2.5 μL Abltide synthetic peptide substrate, biotin-tagged        (Millipore, Temecula, Calif.)        Incubate at 30° C. for 10 min.;        Stop by the addition of 12.5 μL 7.5M guanidine HCL to each        reaction, vortex.        Spot 12.5 μL on SAM2 biotin capture membrane (Promega Corp.,        Madison, Wis.)        Wash the membrane (4×2M NaCl; 4×2M NaCl, 1% H₃PO₄, 2×H₂O, at        room temp.)        Kinase activity was determined by scintillation counting.        The Scintillation count: final drug concentration shown        Each assay was performed in duplicate. The counts per minute        measured were as follows and the average of the two assays is        shown in the right hand column:

CPM AVERAGE 1. DMSO (vehicle) 2837 2897 2. DMSO (vehicle) 2956 1. 10 μMGleevec 308 296 2. 10 μM Gleevec 284 1. 30 μM Gleevec 145 126 2. 30 μMGleevec 107 1. 100 μM Gleevec 51 50 2. 100 μM Gleevec 48 1. 10 μMDesmethyl imatinib 540 595 2. 10 μM Desmethyl imatinib 649 1. 30 μMDesmethyl imatinib 149 149 2. 30 μM Desmethyl imatinib lost tube 1. 100μM Desmethyl imatinib 5 107 2. 100 μM Desmethyl imatinib 119 1. 10 μMpara-diaminomethylbenzene 3HCl 2326 2170 2. 10 μMpara-diaminomethylbenzene 3HCl 2013 1. 30 μM para-diaminomethylbenzene3HCl 1939 1848 2. 30 μM para-diaminomethylbenzene 3HCl 1756 1. 100 μMpara-diaminomethylbenzene 3HCl 1275 925 2. 100 μMpara-diaminomethylbenzene 3HCl 575 1. No Abltide Substrate 13 11 2. NoAbltide Substrate 8

The data are shown in FIGS. 8 and 9. FIG. 8 shows a semilog graph plotof measured Abl kinase activity in the presence of each of the drugs atconcentrations from 0 to 100 μM. Imatinib substantially inhibits Ablkinase even at the lowest concentration tested, 10 μM. N-desmethylimatinib inhibits Abl kinase less than does imatinib, and treatment withimatinib para-diaminomethylbenzene trihydrochloride shows a markedlylower level of Abl kinase inhibition even at the highest concentrationtested, 100 μM.

FIG. 9 shows a selectivity graph showing the ratio of the folddifference in Aβ-lowering activity for each compound (compared toimatinib) to the kinase inhibitor activity for that compound at each ofthe three concentrations shown. Imatinib is the reference compound sothe ratio value for this drug is set to 1.

N-desmethyl imatinib shows 3.8 to 4.8-fold improvement over imatinib inselectivity. Imatinib para-diaminomethylbenzene trihydrochloride showedthe greatest selectivity. At the 30 μM concentration, theparadiaminobenzene composition exhibited about a 3.7 fold greateractivity in lowering Aβ, with only 1/16^(th) of the activity of imatinibin the Abl kinase assay, resulting in a selectivity ratio of nearly 60.

All publications and patents mentioned in the above specification areherein incorporated by reference. Various modifications and variationsof the described compositions and methods of the invention will beapparent to those skilled in the art without departing from the scopeand spirit of the invention. Although the invention has been describedin connection with specific preferred embodiments, it should beunderstood that the invention as claimed should not be unduly limited tosuch specific embodiments. Indeed, various modifications of thedescribed modes for carrying out the invention that are obvious to thoseskilled in the relevant fields are intended to be within the scope ofthe present invention.

We claim:
 1. A method of treating a subject having a brain Aβ disorderor predisposition to a brain Aβ disorder, comprising peripherallyadministering a compound that modulates production of Aβ in a peripheraltissue, wherein said compound is an imatinib derivative displayingreduced protein kinase inhibition compared to imatinib, wherein thecompound is N-desmethyl imatinib or imatinib para-diaminomethylbenzeneor a mixture of N-desmethyl imatinib and imatinibpara-diaminomethylbenzene.
 2. The method of claim 1, wherein the brainAβ disorder is Alzheimer's disease.
 3. The method of claim 1, whereinsaid modulation comprises reducing production of Aβ in said peripheraltissue.
 4. The method of claim 1, wherein said peripheral tissue isliver.
 5. The method of claim 1, wherein said imatinibpara-diaminomethylbenzene is in the form of a mesylate salt.
 6. Themethod of claim 1, wherein said N-desmethyl imatinib is in the form of amesylate salt.
 7. A method, comprising: a) assessing a subject for thepresence of a brain Aβ disorder or predisposition to a brain Aβdisorder; b) peripherally administering a compound that modulatesproduction of Aβ, wherein said compound does not substantially penetratethe blood brain barrier, wherein said compound is imatinibpara-diaminomethylbenzene, or is N-desmethyl imatinib, or is a mixtureof imatinib para-diaminomethylbenzene and N-desmethyl imatinib; and; c)after said administering of step b), assessing said subject for a brainAβ disorder or progression of a brain Aβ disorder.
 8. The method ofclaim 7, wherein said modulation of production of Aβ comprisesmodulating production of Aβ in the liver of said subject.
 9. The methodof claim 8, wherein said modulation comprises inhibition.
 10. The methodof claim 7, wherein said brain Aβ disorder is Alzheimer's disease. 11.The method of claim 7, wherein said compound comprises an inhibitor of aγ-secretase activity.
 12. The method of claim 7, wherein said assessingcomprises one or more of a mental status evaluation, neuropsychologicaltesting, or brain imaging.
 13. The method of claim 7, wherein saidcompound is in a composition that further comprises a known therapeuticagent for treating, ameliorating, or reducing risk or severity of abrain Aβ-related disorder.
 14. The method of claim 13, wherein saidknown therapeutic agent is selected from the group consisting ofimatinib, cannabinoids, dimebom, prednisone, ibuprofen, naproxyn,indomethacin; statins, selective estrogen receptor molecules,antihypertensives, alpha-blockers, beta-blockers, alpha-beta blockers,angiotensin-converting enzyme inhibitors, angiotensin receptor blockers,calcium channel blockers, diuretics, NSAIDS, and antioxidants.
 15. Themethod of claim 7, wherein said peripherally administering comprisesorally administering.